Clinical Study Protocol RVT -901-3004  
Urovant Sciences GmbH Effective:  12-APR -2019 
Confidential Page | 1 CLINICAL STUDY PROTOCOL 
Study Title: An International Phase 3, Randomized, Double-Blind, Active 
(Tolterodine)-Controlled Multicenter Extension Study to Evaluate 
the Long- Term Safety and Efficacy of Vibegron in Patients with 
Symptoms of Overactive Bladder 
Protocol Number: RVT -901-3004 
Compound Name [INVESTIGATOR_1238]/or Number: Vibegron 
Indication Treatment of Overactive Bladder 
Sponsor: Urovant  Sciences  GmbH  
Viaduktstrasse 8 
4051 Basel  
Switzerland  
Development Phase: 3 
Regulatory Identifier(s): IND# 106,[ADDRESS_723011]-003294-33 
Current Version and Effective 
Date: Version 3.0 
12-APR -2019 
Previous Version(s) and Effective 
Date(s): Version 2.0 
06-FEB-2018 
Study Director:  
, Clinical Development 
Confidentiality Statement 
The information contained in this document, particularly unpublished data, is the property or under 
control of Urovant Sciences GmbH , and is provided to you in confidence as an investigator, potential 
investigator or consultant, for review by [CONTACT_10825], your staff, and an applicable Institutional Review Board or Independent Ethics Committee.  The information is only to be used by [CONTACT_550388].  You will not disclose any of the 
information to others without written authorization from Urovant Sciences GmbH .  except to the extent 
necessary to obtain informed consent from those persons to whom the drug may be administered. 
Study ID: [REMOVED]
This NCT number has been applied to the document for
purposes of posting on clinicaltrials.gov

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723012]/Sponsor 
Information Page  The secondary medical monitor was changed from  
 to . 
3.0 Table of Contents ; List 
of Tables, List of 
Figures  Fields were updated . 
3.0 1 The approximate number of study sites was updated.  
3.0 1; 5.1.1  Reference to electronic completion of questionnaires was 
removed.  
3.0 1; 3; 9.2.1  A clarification was added that primary safety will assess adverse 
events that are treatment -emergent . 
3.0 1; 3 The endpoint categories of “Secondary Efficacy” and 
“Exploratory Efficacy” were renamed to “Secondary” and 
Exploratory”, respectively.  
3.0 1; 3; 9.3.1  The following  endpoints previously  included as  “Secondary 
Efficacy” endpoints were moved to “Exploratory” endpoints . 
3.[ADDRESS_723013].  

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 3 Version  Location of Change  Description of Change  
3.0 1; 9.3; 9. 4.1; 9.4.2;  9.5; 
9.5.1; 9.6 ; former 9.8  
(removed)  The description of statistical methods was revised in accordance 
with statistical analysis only be ing performed for the following  
4 secondary endp oints:  
• Change from baseline (CFB) at Week 52 in average number 
of micturitions  per 24 hours in all OAB patients ; 
• CFB at Week 52 in average number of urge urinary 
incontinence (UUI) epi[INVESTIGATOR_11629] 24 hours in OAB Wet 
patients ; 
• CFB at Week 52 in average number of  urgency epi[INVESTIGATOR_1841] 
(need to urinate immediately) over 24 hours in all OAB 
patients ; 
• CFB at Week 52 in average number of total urinary 
incontinence epi[INVESTIGATOR_17767] 24 hours in OAB Wet patients . 
All analysis will be considered descriptive only.  
3.0 1.1 A Week 12 physical exam was included in the Schedule of 
Activities.  
3.0 1.1; 8.3.[ADDRESS_723014] 
dose of Study Treatment in RVT -901-3004.  
3.0 1.1; 8.3.1  Phrasing was r emoved that limits  the collection of adverse events  
to events “deemed related to study procedures” (all adverse events 
are recorded).  
3.0 4.1 The paragraphs in the study design section were reorganized to 
match the order in the synopsis.  
3.0 6.4; 9.[ADDRESS_723015] an  updated blinding 
strategy  for the study as double -blind, Sponsor open (partially 
unblinded).  
3.0 7.7.1  A clarification was added  that all prior OAB meds should be 
assessed during prior medications review.  
3.0 7.7.3  A clarification was added that prohibition of medications with a 
narrow therapeutic index is specific only to the example drugs 
provided . 
3.0 7.8; 9.3.1  A clarification was added for the definition of “Complete Diary 
Day”.  
3.0 8.3.3  A clarification was added that overdose events that do not result 
in an adverse event will be reported as a protocol deviation in the 
eCRF.  
3.0 1; 9.4  “Extension” was added t o analysis population names to 
distinguish analysis sets from this study versus RVT -901-3003.  
2.0 Cover page  Added Basel address; changed study director contact . 
2.0 Global  Minor typographical/grammatical errors were corrected.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723016]/Sponsor 
Information Page  Update  to  and  to 
 to reflect new companies.  
2.0 Table of Contents  Updated all page numbers; Sections 5.4 and 5.4.1:  Replaced 
“Discontinuation” with “Interruption” a nd removed “Withdrawal 
from the Study”.  
2.0 1; 3; 9.3.1  Addition of two exploratory efficacy endpoints 
2.0 1; 2.1  Addition of (RVT -901) after Vibegron to align with Certificate of 
Analysis for product.  
2.0 1; 3; 9.2.2; 9.3.1; 9.5.[ADDRESS_723017]  protocol 
text; updated and realigned footnotes accordingly . 
2.0 5.4; 5.4.1  Replaced “discontinuation” with “interruption”; reversed order of 
sentences.  
2.0 6.6 Removed study medication rechallenge in patients with a grade 3 
or higher drug -related AE reported.  
2.0 7 Moved Visit Reminders to 7.10.  
2.0 7.8; 7.8.1 Updates to Patient Voiding Diary instructions, training, and 
description . 
2.0 7.9; 7.9.1; 7. 9.2 Updates to Urine Volume Collection instructions, training, and 
description . 
2.0 7.10 Update to instructions on Reminders for Diary Collection . 
2.0 7.11; 7.11.1; 7.11.2  Updates to Electronic Diary instructions and training . 
2.0 8.3.1  Updated and condensed section wording  for Reporting Adverse 
Events.  
2.0 8.6 Updated MACCE language to match CAC Charter.  
2.0 8.7 Addition of timeframe around pregnancy and infant outcome.  
1.1 Global  Minor typographical/grammatical errors were corrected.  
1.1 Sponsor Signature [CONTACT_550412]:  This protocol has been 
approved by a representative of Urovant Sciences GmbH.  
1.1 1 Wording in study design description changed from “at 
approximately 100 study sites” corrected to “at approximately 330 
study sites.”  

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 5 Version  Location of Change  Description of Change  
1.1 1; 5.1.1  Inclusion criterion #[ADDRESS_723018] wording in Section  5.2.1.  
1.1 1.1 Footnotes  were updated to include:  a note that paper diaries may 
be used with timing for their collection included; clarification that 
urinalysis will be performed if there is a positive dipstick result.  
1.1 1.1 eDiary completion for the Week  44 Visit was added.  
1.1 5.2.1  Changes were made to description of contraception requirements 
and methods for female patients  
1.1 6.1 “Tablet” or “capsule” descriptors were added to Table 6 -1. 
1.1 6.2 Wording was added to indicate the study treatment should be 
swallowed who le. 
1.1 7.2; 7.16  Clarified that tablet/capsule count will be recorded in the 
interactive voice or web response system rather than case report 
form.  
1.1 7.4 The timing for collection of paper diaries (if used) was added.  
1.[ADDRESS_723019].  
 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723020]/SPON SOR INFORMATION PAGE  
Sponsor Medical Contact/Serious Adverse Event Contact [CONTACT_7171]:  
Role  Name  [CONTACT_550413] -Hours  
Primary 
Medical 
Monitor  Office : 
Mobile :
Fax:   
E-mail:  
 Office : 
Mobile :
Fax:   
E-mail:  
 
Secondary
Medical 
Monitor  Mobile :   
E-mail:  Mobile :   
E-mail:  
 
Conta ct for Serious 
Adverse Events (SAEs)  Email :   
Phone :   
Fax:   
 
 
Study Sponsor:  
This study is sponsored by [CONTACT_329904].  
 

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 8 INVESTIGATOR STATEME NT 
• I confirm agreement to conduct the study in compliance with the protocol.  
• I acknowledge that I am responsible for overall study conduct .  I agree to personally 
conduct or supervise the described study.  
• I agree to ensure that all associates, colleagues, and e mployees assisting in the 
conduct of the study understand their obligations and will comply with the study 
protocol .  Mechanisms are in place to ensure that site staff receives the appropriate 
training and information throughout the study.  
 
   
Principal I nvestigator Name (Printed)   Signature  
   
[CONTACT_550414] -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723021]/ SPONSOR INFORMATION PAGE  ................................ ........................ [ADDRESS_723022] OF FIGURES  ................................ ................................ ................................ ....................... 13 
1. SYNOPSIS  ................................ ................................ ................................ ................. 14 
1.1. Schedule of Activities  ................................ ................................ ................................ .20 
2. INTRODUCTION  ................................ ................................ ................................ ......24 
2.1. Indication  ................................ ................................ ................................ .................... 24 
2.2. Background  ................................ ................................ ................................ ................. 24 
2.3. Study Rationale  ................................ ................................ ................................ ........... 25 
3. OBJECTIVES AND ENDPOINTS  ................................ ................................ ............ 26 
4. INVESTIGATIONAL PLAN  ................................ ................................ ..................... 28 
4.1. Overall Study Design  ................................ ................................ ................................ ..28 
4.2. Treatment Arms and Duration  ................................ ................................ .................... 30 
4.3. Number of Participants  ................................ ................................ ............................... 30 
4.4. Definition of Study Completion by a Patient  ................................ ............................. 30 
4.5. End of Study Definition  ................................ ................................ .............................. 30 
5. STUDY POPULATION  ................................ ................................ ............................. 31 
5.1. Eligibility Criteria  ................................ ................................ ................................ .......31 
5.1.1.  Inclu sion Criteria  ................................ ................................ ................................ ........ 31 
5.1.2.  Exclusion Criteria  ................................ ................................ ................................ .......31 
5.2. On-Study Restrictions  ................................ ................................ ................................ .33 
5.2.1.  Contraception  ................................ ................................ ................................ .............. 33 
5.2.2.  Meals and Dietary Restrictions  ................................ ................................ ................... 33 
5.3. Screen Failure  ................................ ................................ ................................ ............. 34 
5.4. Interruption of Study Treatment  ................................ ................................ ................. 34 
5.4.1.  Temporary Interruption  ................................ ................................ .............................. 34 
5.4.2.  Rechallenge  ................................ ................................ ................................ ................. 34 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723023] to Follow Up  ................................ ................................ ................................ .......35 
5.7. Early Study Termination  ................................ ................................ ............................. 35 
6. STUDY TREATMENT  ................................ ................................ .............................. 36 
6.1. Study Treatments Description  ................................ ................................ .................... 36 
6.2. Administration of Study Treatments  ................................ ................................ .......... 36 
6.3. Study Treatment Assignment  ................................ ................................ ..................... 36 
6.4. Blinding  ................................ ................................ ................................ ...................... 37 
6.4.1.  Unblinding  ................................ ................................ ................................ .................. 37 
6.5. Dose Modification  ................................ ................................ ................................ ......37 
6.6. Treatment Discontinuation and Rechallenge  ................................ .............................. 37 
6.7. Packaging and Labeling  ................................ ................................ .............................. 38 
6.8. Preparation/Handling/Storage/Accountability  ................................ ............................ 38 
6.9. Study Treatment Compliance  ................................ ................................ ..................... 38 
6.10.  Study Treatment Overdose  ................................ ................................ ......................... 38 
6.11.  Treatment after the End of the Study  ................................ ................................ .......... 39 
7. STUDY ASSESSMENTS AN D PROCEDURES  ................................ ...................... 40 
7.1. Order of Assessments  ................................ ................................ ................................ .40 
7.2. Schedul ing Visits  ................................ ................................ ................................ ........ 40 
7.3. Unscheduled Visits  ................................ ................................ ................................ .....40 
7.4. Assignment of Patient Number  ................................ ................................ ................... 40 
7.5. Informed Consent  ................................ ................................ ................................ .......40 
7.6. Inclusion/Exclusion Criteria  ................................ ................................ ....................... 41 
7.7. Prior and Concomitant Medications  ................................ ................................ ........... 41 
7.7.1.  Prior Medications  ................................ ................................ ................................ ........ 41 
7.7.2.  Concomi tant Medications  ................................ ................................ ........................... 41 
7.7.3.  Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014]  ................................ ...................... 42 
7.7.4.  Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]  ................................ ....................... 43 
7.7.5.  Requirements for Use of Stable Therapi[INVESTIGATOR_014]  ................................ ................................ .43 
7.8. Patient Voiding Diary  ................................ ................................ ................................ .44 
7.8.1.  Patient Voiding Diary Training/Re -Training ................................ .............................. 44 
7.9. Urine Volume Diary  ................................ ................................ ................................ ...44 
7.9.1.  Urine Volume Collection Training/Re -Training  ................................ ........................ 45 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 11 7.9.2.  Dispense Urine Collection and Measurement Supplies  ................................ .............. 45 
7.10.  Reminders for Diary Collection  ................................ ................................ .................. 45 
7.11.  Electronic Diary  ................................ ................................ ................................ .......... 45 
7.11.1.  eDiary Device Set -Up and Training  ................................ ................................ ........... 46 
7.11.2.  Device Training/Re -Training  ................................ ................................ ...................... [ADDRESS_723024]-Void Residual Volume  ................................ ................................ ....................... 47 
7.14.  Physical Examination  ................................ ................................ ................................ .47 
7.15.  Electrocardiogram  ................................ ................................ ................................ .......47 
7.16.  Vital Signs  ................................ ................................ ................................ .................. 47 
7.17.  Adverse Events  ................................ ................................ ................................ ........... 48 
7.18.  Clinical Lab oratory Assessments  ................................ ................................ ............... 48 
7.18.1.  Chemistry, Hematology, and Urinalysis (Laboratory Safety Evaluations)  ................ 48 
7.18.2.  Urine β -hCG  ................................ ................................ ................................ ............... 50 
7.19.  IxRS Randomization to Study Treatment  ................................ ................................ ...50 
7.20.  Dispense Double -Blind Study Treatment  ................................ ................................ ...50 
7.21.  Study Treatment Return/Accountability Review  ................................ ........................ [ADDRESS_723025] Abnormalities  ................................ ................................ .................... 58 
8.7. Pregnancy Management and Reporting to the Sponsor  ................................ .............. 59 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 12 8.8. Benefit/Risk Assessment  ................................ ................................ ............................ [ADDRESS_723026] ICAL CONSIDERATIONS  ................................ ................................ .......60 
9.1. Responsibility for Analyses/In -House  Blinding  ................................ ......................... [ADDRESS_723027]/Independent Ethics Committee Requirements  ............... 69 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723028] OF ABBREVIA TIONS  ................................ ................................ ............ 76 
APPENDIX  2. ALGORITHM FOR ASSESS ING LABORATORY VALUE S ........................ 79 
APPENDIX  3. APPROXIMATE BLOOD/TI SSUE VOLUMES 
DRAWN/COLLECTED BY S AMPLE TYPE  ................................ .......................... [ADDRESS_723029] OF T ABLES  
Table  1 RVT -901-3004 Schedule of Activities  ................................ ................................ .......20 
Table  2 RVT -901-3004 Study Treatments  ................................ ................................ .............. 36 
Table  3 Listing of Prohibited Medications  ................................ ................................ .............. 42 
Table  4 Laboratory Tests  ................................ ................................ ................................ ......... 49 
Table  5 Criteria for Determining the Grade/Severity of Adverse Event Terms  ...................... [ADDRESS_723030] OF FIGURES  
Figure  1 RVT -901-3004 Study Schematic  ................................ ................................ ................ 29 
 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 14 1. SYNOPSIS  
Study Title  An International Phase 3, Randomized, Double -Blind, Active (Tolterodine) -
Controlled Multicenter Extension Study to Evaluate the Long -Term Safety and 
Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder  
Protocol Number  RVT -901-3004  
Study Center 
Location(s)  International  
Number of Study 
Centers Planned  ~110 
Study Phase  3 
Target Population  Adult men and women with either:  
• Overactive bladder (OAB) Wet ; or 
• OAB Dry  
Number of Patient s 
Planned  500 
Study Objectives   
Primary Safety 
Objective  • To evaluate the safety and tolerability of vibegron (RVT -901) for up to 52 
weeks in patients with symptoms of overactive bladder (OAB) who 
previously completed treatment in study RVT -901-3003  
Secondary and 
Exploratory  
Objectives  • To evaluate the efficacy of vibegron  in patients with symptoms of OAB  
Study Design  This is an international Phase 3, double -blind, active (tolterodine) -controlled, 
parallel -group, multicenter, 40 -week extension study to evaluate the safety, 
tolerability, and efficacy of vibegron 75  mg in men and women with symptoms of 
overactive bladder syndrome (OAB).  This study is an extension for patient s who 
have completed the Phase 3, double -blind, randomized, 12 -week study RVT -901-
3003.  
Approximately 500 men and women with overactive bladder who completed 
12 weeks in study RVT -901-3003 will be permitted to enroll in this extension 
study, at approximate ly 110 study sites.  
During this extension study, all patients who had been randomized in 
RVT -901-3003 to receive either vibegron 75  mg or tolterodine ER 4  mg will 
continue their same treatment once daily in a blinded fashion for an additional 
40 weeks; pat ients who had been randomized in RVT -901-3003 to the placebo 
group will be randomized 1:1 to receive blinded study treatment of vibegron 
75 mg or tolterodine ER 4  mg once daily for 40 weeks during the extension .  
Thus, through participation in both the RVT -901-3003 study and the RVT -901-
3004 (extension) stud y, patients originally randomized to vibegron or tolterodine 
will receive 52 weeks total of vibegron or tolterodine treatment, and patients 
originally randomized to placebo will receive 40 weeks total of  vibegron or 
tolterodine treatment.  

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723031] study visit of this extension study occurring at Study Treatment 
Week  12.  Following enrollment in this extension study, pati ents will return to the 
clinic for visits at Week  16, Week  24, Week  36, Week  44, and Week  52 (all 
relative to Day 1 of RVT -901-3003).  The Schedule of Activities ( Section  1.1) 
summarizes the assessments/procedures to be performed at each visit.  
This study consists of a randomized double -blind Treatment Period (40  weeks), 
and a Safety Follow -up Period (4 weeks).  A ll patients will have a Follow -up Visit 
approximately 28  days after the patient’s last dose of study treatment (i.e.,  at 
Week  56 for patients who complete the Week  52 Visit, or approximately 4  weeks 
after withdrawal for patients who discontinue the study e arly).  Additionally, 
unscheduled follow -up visit(s) may be arranged for patients with study -related 
safety concerns as needed.  
Study Treatments  The investigator, site staff, and the patients will remain  blinded to the Study 
Treatment during this extension study.  
All treatments are dosed orally, once daily (QD) .  Patient s will receive  one of the 
following  blinded  treatments : 
• Vibegron 75  mg tablet + place bo capsule to match tolterodine ER 
4 mg capsule  (N = 267) 
• Tolterodine ER 4  mg capsule + placebo  tablet  to match vibegron 75  mg tablet  
(N = 233) 
All patients previously randomized to placebo in RVT -901-3003 will be 
randomized 1:1 to receive vibegron 75  mg tablet + placebo capsule to match 
tolterodine ER 4  mg capsule  or tolterodine ER 4  mg capsule + p lacebo tablet 
to match vibegron 75  mg tablet , in this extension study . 
Duration of 
Treatment  40 weeks  
Note :  upon entering this extension  study , all patients will have already received 
2 weeks  of treatment with placebo plus an additional 12 weeks of treatment with 
vibegron, tolterodine, or placebo in the RVT -901-3003 study . 
Eligibility Criteria   
Inclusion Criteria  1. Has completed participation in study RVT -901-3003.  
2. Willing and able to provide written informed consent.  
3. For females of reproductive potential:  Agrees to remain abstinent or use (or 
have their male partner use) an acceptable method of birth control (as 
defined in Section  5.2.1 ) each time the patient has intercourse until the 
Follow -up Visit.  
4. For females of reproductive potential:  Agrees not to donate ova (eggs) until 
at least [ADDRESS_723032] dose of Study T reatment.  
5. Has demonstrated ≥  80% compliance with self -administration of Study 
Treatment in study RVT -901-3003.  
6. Has completed a minimum of 4  Complete Diary Days for study RVT -901-
3003 Week  12. 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 16 7. Is ambulatory and in good general physical and mental health as determined 
by [CONTACT_737].  
8. In the opi[INVESTIGATOR_689], is able and willing to comply with the 
requirements of the protocol, including completing  questionnaires, the 
Voiding Diary, and Voided Volume Diary (will require ability to collect, 
measu re, and record voided volume by [CONTACT_329906]/himself using a graduated 
urine collection and measurement container [provided by [CONTACT_1034], if 
needed]).  
Exclusion Criteria  1. Was unable to complete participation in study RVT -901-3003 for any 
reason.  
2. Has a change in history or current evidence of any clinically significant 
condition, therapy, lab abnormality, or other circumstance that might, in the 
opi[INVESTIGATOR_689], confound the results of the study, interfere with 
the patient’s ability to comply with s tudy procedures, or make participation 
in the study not in the patient’s best interest.  Includes any serious or 
unstable, clinically relevant change in gastrointestinal, renal, hepatic, 
cardiovascular, lymphatic, or psychiatric, or other medical disorder during 
the RVT -901-3003 study  
3. Has coronary or neurovascular interventions planned during the duration of 
the study.  
4. Has uncontrolled hyperglycemia (defined as fasting blood glucose 
>150  mg/dL or 8.33  mmol/L and/or non -fasting blood glucose >200  mg/dL 
or 11.1 mmol/L) based on most recent available lab results in study RVT -
901-3003 or, if in the opi[INVESTIGATOR_689], is uncontrolled.  
5. Has uncontrolled hypertension (systolic blood pressure of ≥ 180  mm Hg 
and/or diastolic blood pressure of ≥ 100  mm Hg) or has a resting heart rate 
(by [CONTACT_117682]) > [ADDRESS_723033] systolic blood pressures ≥ 160  mm Hg or 
< 180 mm Hg are excluded, unless deemed by [CONTACT_11219]/or 
Medical Monitor as safe to proceed in this  study and able to complet e 
the study per protocol; these patients must be on stable hypertension 
medication for at least  90 days.  
b. All patients with signs and symptoms of uncontrolled hypertension, 
regardless of blood pressure measurement, are excluded from the 
study.  These includ e, but are not limited to  neurological symptoms or 
findings, hematuria, proteinuria, retinopathy, unstable angina, acute 
heart failure.  
6. Has clinically significant ECG abnormality which, in the opi[INVESTIGATOR_684], exposes the patient to risk by [CONTACT_348514]  
7. Has alanine aminotransferase or aspartate aminotransferase >  2.0 times the 
upper limit of normal (ULN), or bilirubin (total bilirubin) >  1.[ADDRESS_723034] (or 
> 2.[ADDRESS_723035] if secondary to Gilbert syndrome or pattern consistent with 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 17 Gilbert syndrome) based on most recent available lab results in study RVT -
901-3003.  
8. Has an estimated glomerular filtration rate (eGFR) < 30mL/min/1.[ADDRESS_723036] recent available lab results in study RVT -901-3003.  
9. Use of any prohibited medications as detaile d in Section  7.7.3 . 
10. Plans to initiate or change the dosing of any medications listed in 
Section  7.7.5  during the study that in the opi[INVESTIGATOR_550378].  
11. Has an allergy, intolerance, or a history of a significant clinical or laboratory 
adverse experience associated with any of the active or inactive component s 
of the vibegron formulation or tolterodine formulation.  
12. Is currently participating or has participated in a study with an 
investigational compound or device within 28 days of signing informed 
consent, not including participation in study RVT -901-3003.  
13. Has a history of significant drug or alcohol abuse/dependence within a year 
of informed consent, as assessed by [CONTACT_093].  
14. Has a varying sleep schedule anticipated during times when the voiding 
diaries are to be completed.  
Endpoints   
Primary Safety  • Incidence of any  treatment -emergent  adverse event by [CONTACT_550389]  • Change from baseline (CFB) at Week  52 in average number of micturitions 
per 24 hours in all OAB patients  
• CFB at Week  52 in average number of urge urinary incontinence (UUI) 
epi[INVESTIGATOR_11629] 24 hours in OAB Wet patients  
• CFB at Week  52 in average number of urgency epi[INVESTIGATOR_1841] (need to urinate 
immediately) over 24 hours in all OAB patients  
• CFB at Week  52 in average number of total urinary incontinence ep isodes 
over 24 hours in OAB Wet patients  
Exploratory 
Endpoints  

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 18 

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 19 Statistical Methods   
Sample Size 
Estimation  Five hundred (500) patients rolling over from study RVT -901-3003, in addition to 
other long -term safety data with vibegron, is sufficient to characterize the long -
term safety profile of vibegron 75  mg once daily and satisfies the International 
Conference o n Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) guidance for 1 -year exposure.  
Safety  Safety assessments will include treatment -emergent adverse events, clinical 
laboratory tests, physical examinations, vital signs, and 12 -lead ECGs.  Safety 
analyses will be based on all patients who receive any amount of blinded study 
drug (through Week  52 of this extension study).   Two treatment groups  will be 
used for reporting of safety data  and will be determined based on randomized 
treatment in RVT -901-[ADDRESS_723037] completed the 12 -week treatment period in RVT -
901-3003 and enrolled into  this extension study.  
The efficacy endpoints  of change from baseline in average number of micturitions,  
average number of UUI epi[INVESTIGATOR_1841] , average number of urgency epi[INVESTIGATOR_1841] , and 
average number of total incontinence epi[INVESTIGATOR_550379]  a 
mixed model for repeated measure (MMRM) with restricted maximum likelihood 
estimation.  The analysis model for each efficacy endpoint will include terms for 
treatment, visit, baseline stratification factors  (those found to be significant in 
RVT -901-3003) , baseline score, and interaction of visit by [CONTACT_3148].  An 
unstructured covariance matrix will be used to model the correlation among 
repeated measurements.  The Kenward -Roger adjustment will be used with 
restricted (or residual) maximum lik elihood (REML) to make statistical inference.  
Adjusted  means for each treatment group  and visit  will be estimated  along with 
95% confidence intervals.  No forma l statistical comparisons will be ma de.  Only 
the 52-week subjects  (those on active treatment i n RVT -901-3003 and in 
RVT -901-3004 ) will be included in the model.  
Descriptive statistics will be used to summarize all efficacy  endpoints.  Summaries  
of efficacy endpoints will be presented  by [CONTACT_550390] 4 treatment 
group s will be  determined by [CONTACT_550391] -901-3003 and 
RVT -901-3004.   Baseline will be the RVT -901-3003 baseline.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 20 1.1. Schedule of Activities  
Table  1 RVT -901-3004 Schedule of Activities  
Study Period:   Treatment  Safety Follow -up/ 
Unscheduled  
Visit Number:  Visit #6  Visit #7  Visit #8  Visit #9  Visit #10  Visit #11  UNS #  Visit #12  
Visit Name:  [CONTACT_10585]  12 Week  16 Week  24 Week  36 Week  44 Week  52 
or Early WD  Unsch -
eduled23 Follow -
up24 
Study Day:  85 113 169 253 308 365  393 or 
WD + 28  
Permitted Visit Window:  ± 3 Days  ± 3 Days  ± 3 Days  ± 3 Days  ± 3 Days  ± 3 Days   ± 3 Days  
Informed Consent  X1        
Inclusion/Exclusion Criteria Eligibility Review  X1        
Electronic Diary (eDiary) 2:         
eDiary Device          
Device Function Check4 X3 X X X X X X  
Device Re -Training5 X1 X X X X  X  
Collect eDiary Device       X   
Patient Voiding Diary:          
Voiding Diary Re -Training6 X1 X X  X X X  
Patient Completes Voiding Diary7 X* X X  X X   
Urine Volume Diary:          
Voided Volume Diary Re -Training6 X1 X X  X X X  
Patient Completes Voided Volume Diary8 X* X X  X X   
Diary and Visit Reminders          
Phone Calls/ Optional SMS reminders9 X* X X  X X   
Patient Reported Outcomes (PROs)10:         
Global Impression Items (PGI -Severity, PGI -Control, 
PGI-Frequency, PGI -Leakage, and PGI -Change)  X*  X   X   
Overactive Bladder Questionnaire (OAB -q LF)  X*  X   X   
Work Productivity and Activity Impairment 
Questionnaire -Urinary Symptoms (WPAI -US) X*  X   X   
EQ-5D X*  X   X   
Post-Void Residual (PVR) Volume11 X*  X   X   
Physical Exam12 X1      X X 
ECG13 X1      X  
Vital Signs14 X* X X X X X X X 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 21 Study Period:   Treatment  Safety Follow -up/ 
Unscheduled  
Visit Number:  Visit #6  Visit #7  Visit #8  Visit #9  Visit #10  Visit #11  UNS #  Visit #12  
Visit Name:  [CONTACT_10585]  12 Week  16 Week  24 Week  36 Week  44 Week  52 
or Early WD  Unsch -
eduled23 Follow -
up24 
Study Day:  85 113 169 253 308 365  393 or 
WD + 28  
Permitted Visit Window:  ± 3 Days  ± 3 Days  ± 3 Days  ± 3 Days  ± 3 Days  ± 3 Days   ± 3 Days  
Adverse Event Review15 ============================================================================== ➔ 
Serious Adverse Events16 ============================================================================== ➔ 
Concomitant Medication Review17 ============================================================================== ➔ 
Clinical Laboratory Assessments:          
Chemistry  X* X X   X X X 
Hematology  X* X X   X X X 
Urine Dipstick18 X* X X   X X X 
Urine Pregnancy -hCG (women)19 X* X X X X X X X 
IxRS Randomization to Study Treatment  X1        
Dispense Study Treatment20 X1 X X X X  X  
Study Treatment Return/Accountability Review21 X* X X X X X   
Administer Witnessed Dose of Study Treatment22 X1        
Abbreviations :  IxRS, interactive voice or web response system; WD, withdrawal; β -hCG, β -human chorionic gonadotropin  
 
Table Footnotes:  
Week  12 
1. Patients continuing from the RVT -901-3003 study at Week  12 require additional study procedures for the RVT -901-3004 extension 
study . 
* Activities collected at Week  12 Visit in RVT -901-3003 . 
Electronic Diary (eDiary)  
2. The Electronic Diary (eDiary ) for this study includes both the Patient Voiding Diary and the Urine Volume Diary, and will be 
implemented via an eDiary device (provisioned smartphone) .  A paper diary will be provided to all patients to be used as a back -up 
when necessary .  If a back -up paper diary is used, it should be collected at the next visit.  
3. The site will update the Subject Status Screen on the eDiary to move the patient to the RVT -901-3004 extension study.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 22 eDiary Device  
4. At each visit during the Treatment Period, site personnel w ill confirm that the eDiary Device is functioning properly . 
5. Specific re -training on device operation will be provided to the patient at each visit.  
Patient Voiding Diary and Urine Volume Diary  
6. Specific re-trainin g on completion of the Voiding Diary and Voi ded Volume Diary will be provide d to the patient at each visit.  
7. The Void ing Diary should be completed by [CONTACT_329911] 7 Diary D ays prior to the Week  16, 24, 44, and 52  Visits.  Patient 
will receive an alert and/or phone call reminder to complete the diary.  
8. The Voided Volume collection and Voided Volume Diary completion should be performed by [CONTACT_329912] (1) of the [ADDRESS_723038] day of each diary 
collection period  (or next business day) .  Patient may consent to additional SMS Text reminders (where available) . 
Patient Reported Outcomes (PROs)  
10. Vital  signs, followed by [CONTACT_550392] , will be the first procedure performed at visits that include PRO administration .  
Questionnaires will be administered  on paper  at the site in the order listed in the Schedule of Activities . 
Post Void Residual Volume  
11. All efforts will be made to ensure the same device and operator are used for all PVR volume measurements for individual patients  (in 
study RVT -901-3003 and RVT -901-3004). 
Physical/ ECG/ Vitals  
12. A Complete Physical Exam will be performed at the Follow -up Visit . 
13. A single 12 -lead ECG will be obtained at Week  12. 
14. Vital Signs includes Blood  Pressure  (average of three measurements taken 1 -2 minutes apart after sitting for 5 min) , Heart Rate, 
Temperature, Respi[INVESTIGATOR_26452], and Weight.  
Adverse Events  
15. Adverse Events wi ll be collected from the time a patient takes the first dose of Study Treatment  in the RVT -901-3004 study until the 
Follow -up Visit is completed.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723039] dose of Study treatment  in the RVT -901-3004 study until 
the Follow -up Visit is completed.  
Concomitant Medications  
17. Concomitant medications from RVT -901-3003 will be reviewed and confirmed to be stable .  Concomitant medications will be recorded 
at each study visit and at any Unscheduled  Visits.  
Labs  
18. At Weeks 36 and 44, the Urine Dipstick will only be performed if clinically indicated (e.g. , symptoms of urinary retention or urinary 
tract infection) .  Urinalysis will be performed only if the urine dipstick tests positive for the presence o f leukocytes, nitrites, or blood 
cells, and will be performed by [CONTACT_6626].  
19. Urine beta -human chorionic gonadotropin (β -hCG) will be tested for women of childbearing potential only.  
Dosing/Drug  
20. Dosing will occur every  day from the Witnessed Dose on the day of the Week  12 Visit through the day before the Week  52 Visit.  
21. Study Treatment bottles  should be returned by [CONTACT_329914] .  Clinic staff will perform accountability and review any 
discrepancies with the patient du ring the visit.  
22. All patients will take their dose of Study Treatment on the day of the Week  12 Visit at the site as a witnessed dose .  The date and time 
of Study Treatment dosing will be recorded.  
Follow -up/Unscheduled  
23. Unscheduled Visits and the specific p rocedures performed at these visits will be determined by [CONTACT_737], as clinically indicated .  
The procedures indicated in the Schedule of Activities will be performed at these visits, as clinically indicated, based on t he purpose of 
the visit (e.g. , follow -up for an adverse event or abnormal laboratory test , dispense study treatment medication ).  The reason for the visit 
will be captured in the source documents . 
24. For patients who complete the study or who Withdraw from the study early for any reason,  a Follow -up Visit should be performed 
approximately [ADDRESS_723040] dose of Study Treatment (on Study Day 393 or approximately 28 days after a patient ’s Withdrawal 
from the study) .  When a patient withdraws from the study prior to study completion, all applicable activities scheduled for the Week  52 
Visit should be performed at the time of withdrawal.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 24 2. INTRODUCTIO N 
2.1. Indication  
Vibegron (RVT -901) is currently in development to reduce urge urinary incontinence, urgency, 
and urinary frequency in patients with overactive bladder (OAB).  
2.2. Background  
OAB affects approximately 16% of the population in the US and EU .  Prevalence increases with 
age, affecting approximately 1/3 of people 75 years  and older [ Stewart , 2003 ; Milsom , 2001 ].  
The In ternational Continence Society (ICS) defines OAB as urgency, with or without urge 
incontinence, usually associated with frequency and nocturia [ Abrams , 2002].  Urgency is 
defined as a sudden compelling desire to void which is difficult to defer .  Urge urinary 
incontinence (UUI) is the involuntary loss of urine accompanied by [CONTACT_165547] (referred to as OAB 
Wet) and is present in approximately one -third of patie nts with OAB [ Stewart , 2003; 
Milsom , 2001] .  In the absence of incontinence, OAB is referred to as OAB Dry .  UUI is 
distinguished from stress urinary incontinence, which is the involuntary loss of urine on effort or 
physical exertion (e.g., sporting activities), or on sneezing or coughing .  When both components 
are present, the classification is mixed urinary incontinence and the Investigator will make a 
determination of either urgency or stress specified as the predominant component.  
Currently, the p redominant class of drugs used to treat OAB is antimuscarinics .  The clinical use 
of antimuscarinics is limited by [CONTACT_329915] -based 
side effects including dry mouth, constipation, and the potential for CNS advers e effects (e.g. , 
cognitive impairment) .  High discontinuation rates have been observed for both tolterodine and 
oxybutynin, two commonly prescribed antimuscarinics, in both clinical trials and marketed 
settings [ D’Souza , 2008 ; Lawrence , 2000 ].  In a study evaluating the discontinuation rate of new 
prescriptions for tolterodine ER or oxybutynin, the mean time to discontinuation was 45 to 
60 days, and over 55% of patients never refilled their original prescription [ Lawrence , 2000] .  At 
six months, less than 1/3 of patients were still refilling their presc riptions .  The lack of efficacy 
or inability to tolerate antimuscarinics leaves patients with few alternative treatment options .  As 
such, there is a clear unmet medical need for better treatment options for patients with OAB .  In 
addition, recent evidence  from observational studies suggests that higher cumulative 
anticholinergic use is associated with an increased risk of dementia [ Gray , 2015 ; Gray , 2016 ]. 
Beta-3 adrenergic receptor (β 3-AR) agonists demonstrated efficacy in alleviating symptoms of 
OAB [ Chapple , 2009 ; Chapple , 2010 ; Chapple , 2012 ].  To date, one β 3-AR agonist, mirabegron 
(Astellas Pharma Global Development, Inc.), has received marketing approval in Japan and the 
[LOCATION_002] for the treatment of OAB .  Reductions  in micturition frequency, urinary 
incontinence and urgency epi[INVESTIGATOR_1841], and increases in mean volume voided per micturition were 
observed with mirabegron [ Chapple , 2009; Chapple , 2010; Chapple , 2012 ].  Cross -study 
comparisons of the clinical profiles of β 3-AR agonists with the antimuscarinic, DETROL® LA 
(tolterodine tartrate extended release, hereafter referred to as tolterodine ER), suggest that β 3-AR 
agonists possess similar efficacy for the treatment of OAB with an improved tolerability profile 
[Chapple , 2009; Van Kerrebroeck , 2001 ].  A recent publication demonstrated that patients 
prescribed mirabegron remained on treatment longer and showed greater adherence than those 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 25 prescribed traditional antimuscarinics, and mirabegron was associated with a favorable safety 
and tolerability profile [ Chapple , 2017 ]. 
Vibegron is a potent, highly selective, orally available β 3-AR agonist demonstrating >9,000 fold 
selectivity for activation of 3-AR over 2-AR and 1-AR in cell based in vitro assays .  
Βeta-adrenergic receptors (β -AR) are prototypic G -protein coupled receptors expressed on the 
surface of cells and mediate intracellular signaling via coupling to G proteins and increasing 
levels of intracellular cyclic adenosine monophosphate (cAMP) .  β3-ARs are widely distributed 
in humans and are the most prevalent β -AR subtype expressed on human detrusor smooth 
muscle [ [COMPANY_005] , 2000 ].  In isolated huma n bladder smooth muscle, activation of β 3-AR using 
subtype -selective agonists results in smooth muscle relaxation suggesting a role of β 3-AR 
agonists during the filling phase of the micturition cycle [ Yamaguchi , 2002; Biers , 2006 ].  In 
rodent models of bladder overactivity, β 3-AR agonists relax bladder smooth muscle and suppress 
non-neurogenic and neurogenic detrusor over activity [ [COMPANY_005] , 2000 ; Woods , 2001 ; 
[COMPANY_005] , 2002 ; Kaidoh , 2002 ].  In rhesus monkeys, dose -dependent increases in bladder capacity 
and decreases in  micturition pressure were observed with vibegron .  Bladder capacity was further 
increased by [CONTACT_329916].  
2.3. Study Rationale  
The use of vibegron in a large Phase 2b study (Study 008) in patients with OAB has 
demons trated encouraging safety, tolerability, and efficacy results .  Furthermore, Phase 3 data in 
Japan (Studies 301 and 302) have demonstrated that vibegron is a safe, well tolerated, and 
effective therapy for OAB patients .  Given there are still OAB patients that do not reach their 
treatment goals with currently approved therapi[INVESTIGATOR_014], there remains an unmet need for new OAB 
therapi[INVESTIGATOR_15128] a favorable safety, tolerability, and efficacy profile .  This study is designed to 
evaluate the long-term safety, tolerability , and efficacy of vibegron 75  mg administered  once 
daily  in patients with OAB . 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 26 3. OBJECTIVES AND ENDPO INTS  
Objectives  Endpoints  
Primary Safety  
• To evaluate the safety and tolerability 
of vibegron for up to 52 weeks in 
patients with symptoms of overactive 
bladder (OAB) who previously 
completed treatment in study RVT -
901-3003  • Incidence of any treatment -emergent adverse event by 
[CONTACT_310185] d preferred term  
Secondary and Exploratory  
• To evaluate the efficacy of vibegron 
in patients with symptoms of OAB  Secondary Endpoints:  
• Change from baseline (CFB) at Week  52 in average 
number of micturitions per 24 hours in all OAB patients  
• CFB at Week  52 in average number of urge urinary 
incontinence (UUI) epi[INVESTIGATOR_11629] 24 hours in OAB Wet 
patients  
• CFB at Week  52 in average number of urgen cy 
epi[INVESTIGATOR_1841] (need to urinate immediately) over 24 hours in 
all OAB patients  
• CFB at Week  52 in average number of total urinary 
incontinence epi[INVESTIGATOR_17767] 24 hours in OAB Wet 
patients  
Exploratory Endpoints:  

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 27 Objectives  Endpoints  

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 28 4. INVESTIGATIONAL PLAN  
4.1. Overall Study Design  
This is an international Phase 3, randomized, double -blind, active (tolterodine) -controlled, 
40-week extension study to evaluate the safety, tolerability, and efficacy of vibegron [ADDRESS_723041] completed the Phase 3, double -blind, 
randomized, 12 -week study RVT -901-3003 , which evaluated the efficacy, safety, and tolerability 
of vibegron 75  mg administered once daily in patients with OAB .  Approximately 500 men and 
women wi th overactive bladder who completed 12 weeks in study RVT -901-3003  will be 
permitted  to enroll  in this extension study . 
During the study, all patients who had been randomized in RVT -901-3003 to receive either 
vibegron 75  mg or tolterodine ER 4  mg will cont inue their same treatment once daily in a 
blinded fashion for 40  weeks during the extension; patients who had been randomized to the 
placebo group in RVT -901-3003 will be randomized 1:1 to receive blinded study treatment of 
vibegron 75  mg or tolterodine ER  4 mg once daily for 40 weeks during the extension.   Thus, 
through participation in both the RVT -901-3003 study and the RVT -901-3004 (extension) stud y, 
patients originally randomized to vibegron or tolterodine will receive [ADDRESS_723042] 
study visit of this extension study occurring at Week  12.  Following enrollment in this extension 
study, patients will return to the clinic for visits at Week  16, Week  24, Week  36, Week  44 and 
Week  52 (all relative to Day 1 of RVT -901-3003).  
The study consists of a randomized double -blind Treatment Period (40  weeks) and a Safety 
Follow -up Period ( 4 weeks) .  All patients will have a Safety Follow -up Visit approximately 
28 days after the patient’s last dose of study treatment (i.e., at Week  56 for patients who 
complete the Week  52 Visit, or approximately 4  weeks after withdrawal for patients who 
discontinue the study early) .  Additionally, unscheduled follow -up visit(s) may be arranged for 
patients with study -related safety concerns as needed.  
Specific procedures to be performed during t he study, as well as their prescribed times and 
associated visit windows, are outlined in the Schedule of Activities ( Table  1).  Details of study  
proce dures are provided in Section  7. 
A schematic of the study design is shown as Figure  1. 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 29 Figure  1 RVT -901-3004 Study Schematic  
 

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 30 4.2. Treatment Arms and Duration  
Refer to Section  6 for full details of Study Treatment s.  Patient s will receive  one of the following  
blinded treatments during this extension study : 
• Vibegron 75  mg tablet + placebo capsule to match tolterodine ER 4  mg capsule; both 
oral and administered once daily  
• Tolterodine ER 4  mg capsule + placebo tablet to match vibegron 75  mg tablet; both 
oral and administered once daily  
Dosing will begin at the Week  12 Visit (i.e., the baseline visit of the extension stud y), and once 
daily dosing of the Study Treatment  will continue through Study Day 364, the day before the 
Week  [ADDRESS_723043] completed the study if she/he completes the Week  [ADDRESS_723044] patient  has either completed the study (see 
Section  4.4 for definition of completion), has discontinued from the study, or is lost to follow -up 
(i.e., the patient  is unable to be contact[CONTACT_108866]).  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723045] completed participation in study 
RVT -901-3003 , and continue to meet all the Inclusion Criteria, and none of the Exclusion 
Criteria .   
5.1.1.  Inclusion Criteria  
1. Has completed participation in study RVT -901-3003 . 
2. Willing and able to provide written informed consent.  
3. For females of reproductive potential :  Agrees to remain abstinent or use (or have their 
male partner use) an acceptable method of birth control (as defined in Section  5.2.1 ) each 
time the patient has intercourse until the Follow -up Visit.  
4. For females of reproductive potential :  Agrees not to don ate ova (eggs) until at least 
[ADDRESS_723046] dose of Study Treatment.  
5. Has demonstrated ≥  80% compliance with self -administratio n of Study Treatment in 
study RVT -901-3003 . 
6. Has completed a minimum of 4  Complete Diary Days  for study RVT -901-3003  Week  12. 
7. Is ambulatory and in good general physical and mental health as determined by [CONTACT_3786].  
8. In the opi[INVESTIGATOR_689], is able and willing to comply with the requirements of 
the protocol, including completing questionnaires, the Voiding Diary, and Voided 
Volume Diary ( will require ability to collect, measure, and record voided volume by 
[CONTACT_329906]/ himself using a graduated urine collection and measurement container  [provided 
by [CONTACT_1034], if needed]) . 
5.1.2.  Exclusion Criteria  
1. Was unable to complete participation in study RVT -901-3003 for any reason.  
2. Has a change in history or current evidence of any clinically significant  condition, 
therapy, lab abnormality , or other circumstance that might, in the opi[INVESTIGATOR_684], confound the results of the study, interfere with t he patient’s ability to 
comply with study procedures, or make participation in the study not in the patient’s best 
interest .  Includes a ny serious or unstable, clinically relevant change in gastrointestinal, 
renal, hepatic, cardiovascular, lymphatic, or psychiatric, or other medical disorder during 
the RVT -901-3003 study  
3. Has coronary or neurovascular interventions planned during the duration of the study.  
4. Has uncontrolled hyperglycemia (defined as fasting blood glucose >150  mg/dL or 
8.33 mmol/L and/or non -fasting blood glucose > 200 mg/dL or 1 1.1 mmol/L) based on 
most recent available lab results in study RVT -901-3003  or, if in the opi[INVESTIGATOR_684], is uncontrolled.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 32 5. Has uncontrolled hypertension (systolic blood pressure of ≥ 180  mm Hg and/or dias tolic 
blood pressure of ≥ 100  mm Hg) or has a resting heart rate (by [CONTACT_117682]) > [ADDRESS_723047] systolic blood pressures ≥ 160  mm Hg or < 180  mm Hg are 
excluded, unless deemed by [CONTACT_11219]/or Medical Monitor as safe to 
proceed in this study and able to complete the study per protocol ; these patients must 
be on stable hypertension medication for at least 90 days .   
b. All patients with signs and symptoms of uncontrolled hypertension, regardless of 
blood pressure measurement, are  excluded from the study .  These include, but are not 
limited to neurological symptoms or findings, hematuria, proteinuria, retinopathy, 
unstable angina, acute heart failure.  
6. Has clinically significant ECG abnormality which, in the opi[INVESTIGATOR_22909], 
exposes the patient to risk by [CONTACT_6231]  
7. Has alanine aminotransferase or aspartate aminotransferase > 2.0 times the upper limit of 
normal (ULN), or bilirubin (total bilirubin) > 1.[ADDRESS_723048] (or > 2.[ADDRESS_723049] if secondary to 
Gilbert syndro me or pattern consistent with Gilbert syndrome)  based on most recent 
available lab results in study RVT -901-3003 . 
8. Has an estimated glomerular filtration rate (eGFR) < 30mL/min/1.[ADDRESS_723050] 
recent available lab results in study RVT -901-3003 . 
9. Use of any prohibited medications as detailed in Section  7.7.3 . 
10. Plans to initiate or change the dosing of any medications listed in Section  7.7.5  during the 
study  that in the opi[INVESTIGATOR_550380] . 
11. Has an allergy, intolerance, or a history of a significant clinical or laboratory adverse 
experience associated with any of the active or inactive components of the vibegron 
formulation or tolterodine formulation.  
12. Is currently participating or has participated in a study with an investigational compoun d 
or device within 28 days of signing informed consent, not including participation in study 
RVT -901-3003.  
13. Has a history of significant drug or alcohol abuse/dependence within a year  of informed 
consent, as assessed by [CONTACT_093] . 
14. Has a varying sleep  schedule anticipated during times when the voiding diaries are to be 
completed.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723051] agree to use (or have their male partner use) a highly effective 
contraception, unless any of the following apply:  
• has reached natural menopause, defined as at least 12 months of spontaneous 
amenorrhea without an alternative medical cause;  
• is permanently sterile, following hysterectomy, bilateral salpi [INVESTIGATOR_1656], or bilateral 
oophorectomy.  
The highly effective methods of contraception include the following:  
• combined (estrogen - and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation, which may be oral intravaginal or tran sdermal  
• progestogen -only hormonal contraception associated with inhibition of ovulation, 
which may be oral, injectable, or implantable  
• intrauterine device (IUD)  
• intrauterine hormone -releasing system (IUS)  
• bilateral tubal occlusion (including ligation and blockage methods such as Essure™ at 
least 6 months prior to the initial Screening Visit [patients with Essure must have 
prior confirmation of tubal occlusion by [CONTACT_31084][INVESTIGATOR_8913]])  
• sexual partner(s) who was vasectomized at least 6 months prior to the Scr eening Visit  
• sexual abstinence from heterosexual intercourse, as a preferred lifestyle; periodic 
abstinence is not acceptable  
Patients will be provided with information on acceptable methods of contraception as part of the 
informed consent process and will  confirm when they sign a consent form they understand the 
requirements for avoidance of pregnancy during the course of the study.  
These methods of contraception are only effective when used consistently, correctly, and in 
accordance with the product label .  The Investigator is responsible for ensuring that patients 
understand how to properly use these methods of contraception.  
5.2.2.  Meals and Dietary Restrictions  
Patients may consume a normal, regular diet and take their Study Treatment daily without regard 
to food or other medications.  
Patients do not need to fast prior to laboratory draws.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 34 5.3. Screen Failure  
For patients who provide informed consent and subsequently do not meet eligibility criteria or 
withdraw consent  prior to randomization in RVT -901-3004,  study s ite personnel should 
document the screen failure in the patients' source documents .  The documentation should 
include demographics and medical history, the reason for screen failure, the eligibility criteria 
reviewed, procedures performed, etc.  
The screen failure should be reported promptly to  interactive voice or web response system  
(IxRS ). 
5.4. Interruption  of Study Treatment  
5.4.1.  Temporary Interruption  
The medical monitor should be contact[CONTACT_329921] >  [ADDRESS_723052] occur .  Every effort should be made to 
establish and document the possible reasons for withdrawal .  A patient may be withdrawn by [CONTACT_550393], the study plan is 
violated, or for administrative and/or other safety reasons .  The patient may be discontinued from 
further study participation after discussion between the Investigator and the Sponsor clinical 
monitor (or designee) if the pati ent requires therapy with any excluded medication .  Medications 
that may cause a patient to be discontinued have been described in Section  7.7.[ADDRESS_723053] be discontinued from the study for any of the following reasons:  
• The patient or legal representative (such as a legal guardian) withdraws consent.  
• Study treatment administration is interrupted for more than 21 consecutive days.  
• The patient h as a medical condition or personal circumstance which, in the opi[INVESTIGATOR_173546]/or Sponsor, places the patient at unnecessary risk through 
continued participation in the study or does not allow the patient to adhere to the 
requirements of the  protocol.  
• The patient has a confirmed positive serum pregnancy test.  
• The patient is unable to complete the study procedures successfully, including 
completion of the Patient Voiding Diary.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 35 When a patient withdraws from the study prior to study completion,  all applicable activities 
scheduled for the Week  52 Visit should be performed at the time of withdrawal .  Any adverse 
events that are present at the time of withdrawal should be followed in accordance with the 
safety requirements outlined in Section  8. 
Once a patient is withdrawn, he/she shall not be allowed to enroll again.  
5.6. Lost to Follow Up  
Should a patient fail to attend a required study visit, the site should attempt to contact [CONTACT_329923] -schedule the missed visit as soon as possible .  The site should also counsel the patient on 
the importance of maintaining the assigned visit schedule and ascertain whether or not the patient 
wishes to a nd/or should continue in the study based on previous non -compliance .  In cases where 
the patient does not return for the rescheduled visit or cannot be reached to reschedule the missed 
visit, the site should make every effort to regain contact [CONTACT_550394] a primary reason of “Lost to Follow -up”.  
Including at least three documented attempts to contact [CONTACT_102] (i.e., phone, email, or certified 
letter) .  Efforts to establish the possible  reason for discontinuation should be documented.  
5.7. Early Study Termination  
The study may be terminated early if the extent (incidence and/or severity) of emerging 
effects/clinical endpoints is such that the risk/benefit ratio to the study population as a wh ole is 
unacceptable .  In addition, further recruitment in the study overall or at a particular study site 
may be stopped due to insufficient compliance with the protocol, Good Clinical Practice (GCP) 
and/or other applicable regulatory requirements, procedu re-related problems or the number of 
discontinuations for administrative reasons is too high.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 36 6. STUDY TREATMENT  
6.1. Study Treatments  Description  
Study Treatment is defined as vibegron  or tolterodine .  All Study Treatment s will be provi ded by 
[CONTACT_1034].  
Each Study Treatment  is descr ibed in Table  2. 
Table  2 RVT -901-3004 Study Treatments  
Study Treatment  Dose  Frequency ; Route of 
Administration ; 
Description  Use 
Vibegron  75 mg Once daily; oral ; tablet  Experimental  
Tolterodine ER  4 mg Once daily; oral ; capsule  Active control  
Placebo to match vibegron 75  mg NA Once daily; oral ; tablet  Blinding  
Placebo to match tolterodine ER 4  mg NA Once daily; oral ; capsule  Blinding  
 
6.2. Administration of Study Treatment s 
Throughout the study, all Study Treatments will be taken by [CONTACT_329925] [ADDRESS_723054] to meals.  
All doses of Study Treatment  will be taken by [CONTACT_144294] . 
If a patient forgets to take Study Treatment in the morning, the missed dose should be taken as 
soon as possible on the same calendar day .  However, if a dose is missed for an entire calendar 
day, the missed dose should NOT be taken on the following calendar day .  This will be recorded 
as a missed dose.  
6.3. Study  Treatment Assignment  
Randomization will occur centrally using an IxRS .  Enrollment in this extension study will be  
capped at approximately 500 patients .  There are two treatment arms in this study:  
• Vibegron 75  mg + placebo to match tolterodine ER 4  mg 
• Tolterodine ER 4  mg + placebo to match vibegron 75  mg 
Patients will be assigned to double -blind Study Treatment as fol lows:  
• All patients randomized  to vibegron 75  mg in study RVT -901-3003  will be assigned 
to take vibegron 75  mg during the 40 -week extension study.  
• All patients randomized to placebo in study RVT -901-3003 will be randomized 1:1 
and assigned to take vibegron 75 mg or tolterodine ER 4  mg during the 40 -week 
extension study.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 37 • All patients randomized to tolterodine ER 4  mg in study RVT -901-3003 will be 
assigned to take tolterodine ER 4  mg during the 40 -week extension study.  
6.4. Blinding  
A double -blind/masking technique  will be used :  vibegron and its matching placebo and 
tolterodine ER and its matching placebo will be packaged identically so that treatment 
blind/masking is maintain ed.  The patient  and the Investigator  involved in the treatment or 
clinical evaluation of the patients  are unaware of the treatment group assignments.   Specific 
Sponsor personnel and delegate(s)  will be partially unblinded once RVT -901-3003 reaches 
database lock.  However, Sponsor personnel and delegates involved in patient -level decisions 
will remain blinded.   Therefore, the blinding strategy for the RVT -901-3004 study will be 
double -blind, Sponsor open (partially unblinded).  
At the end of the study  (including the 28 -day Follow -up Period) , the official, final database will 
be frozen and unblinded after medical/scientific review has been performed, and data have been 
declared final and complete .  The Sponsor will be granted access to the unblinded database in 
order to analyze the data .  A clinical study report will be prepared after all pa tients complete the 
study.  
6.4.1.  Unblinding  
All efforts should be made to contact [CONTACT_329926] .  In consultation with the Medical Monitor, IxRS  
should be used for emergency unblinding treatment assignment in the event that this is required 
for patient safety.  
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., date and 
reason) must be documented promptly, and  the Sponsor notified as soon as possible .  Only the 
Principal Investigator [INVESTIGATOR_329876]’s code should be unblinded .  Site 
personnel and Sponsor personnel directly associated with the conduct of the study should not be 
unblinded.  
6.5. Dose Modification  
No dose modifications are allowed.  
6.6. Treatment Discontinuation and Rechallenge  
Refer to Section  8.6.[ADDRESS_723055] of the patient .  (Refer to Table  5 for Criteria for 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 38 Determining the Grade/Severity of Adverse Event Terms) .  Prior to restarting Study Treatment , 
the adverse event must have  improve d to grade 0, 1, or 2.  
If the adverse event that is not related to Study Treatment rema ins grade [ADDRESS_723056] of the patient, Study 
Treatment should be discontinued permanently.  
6.7. Packaging and Labeling  
Clinical supplies will be affixed with a clinical label i n accordance with regulatory requirements .  
Patient s will receive a double -blind  supply of Study Treatment bottles at each study visit  during  
the Treatment Period . 
6.8. Preparation/Handling/Storage/Accountability  
Clinical supplies must be stored in a secure, limited -access location under the storage conditions 
specified on the label.  
Receipt and dispensing of Study Treatment must be recorded by [CONTACT_329927].  
Clinical supplies may not be used for any purpose other than that stated in t he protocol.  
The Investigator is responsible for keepi[INVESTIGATOR_26340], the amount dispensed to and returned by [CONTACT_13935], and the 
amount remaining at the conclusion of the study .  These records will be monitored throughout 
the study.  
For all sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return.  
6.9. Study Treatment Compliance  
If a patient is pers istently noncompliant with the Study Treatment, it may be appropriate to 
withdraw the patient from the study .  Interruptions from the protocol specified treatment plan for 
compliance (≤ 75% or >125%) require consultation between the Investigator and the Sp onsor 
and written documentation of the collaborative decision on patient management.  
6.10. Study Treatment Overdose  
Refer to Section  8.3.3  for Overdose Management .  An overdose is defined as a known deliberate 
or accidental administration of Study Treatment, to or by a study patient, at a dose above that 
assigned to that individual patient according to the study protocol.  
For this study, any dose of vibeg ron or placebo > 2 tablets and any dose of tolterodine or placebo 
> 2 capsules within a 24 -hour window (i.e., > 2 tablets and/or > 2 capsules of blinded Study 
Treatment within a 24 -hour window) is an overdose .  There is no known antidote for an 
overdose.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 39 6.11. Treatment after the End of the Study  
Patients will not receive any additional treatment with the Study Treatment from the Sponsor 
after completion of the study because the indication being studied is not life -threatening or 
seriously debilitating and/or ot her treatment options are available .  The Investigator is 
responsible for ensuring that consideration has been given to the post -study care of the patient’s 
medical condition.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 40 7. STUDY ASSESSMENTS AN D PROCEDURES  
The Schedule of Activities ( Section  1.1) summarizes the study assessments/procedures to be 
performed at each visit .  Individual assessments and procedures are described below.  
It may be necessary to perform these procedures at unscheduled time points if deemed clinically 
necessary by [CONTACT_737] .  Furthermore, additional evaluations/testing may be deemed 
necessary by [CONTACT_11219]/or the Sponsor for reasons related to patie nt safety .  In some 
cases, such evaluation/testing may be potentially sensitive in nature, and thus local regulations 
may require that additional informed consent be obtained from the patient .  In these cases, such 
evaluations/testing will be performed in accordance with those regulations.  
7.1. Order of Assessments  
Vital signs, followed by [CONTACT_329928], will be the first procedures performed at visits that 
include PRO administration .  Blood draws should be performed after PRO administration .  A 
urine pregn ancy test (with a negative result) must be done prior to randomization.  
7.2. Scheduling Visits  
To the extent possible, all visits should occur at the same time across the study between the hours 
of 8 am and 12 pm .  At the end of each visit, the next visit should be scheduled/confirmed .  
Every effort should be made to adhere to the visit scheduling window as described in the 
Schedule of Activities ( Section  1.1) to ensure the patient has an adequate amount of Study 
Treatment to comply with protocol dosing instructions .  Patients will be reminded to complete 
the Patient Voiding Diary and Urine Volume Diary within the 7 days prior to their next visit.  
7.3. Unscheduled Visits  
Unscheduled Visits may be performed at any time during the study whenever necessary to assess 
for or follow -up on adverse events, at the patient’s request, or as deemed necessary by [CONTACT_3786] .  The date and reason for the Unschedule d Visit should be recorded in the source 
documentation .  The specific procedures performed at these visits will be determined by [CONTACT_3786], as clinically indicated .  The recommended minimum procedures are indicated in the 
Schedule of Activities ( Section 1.1). 
7.4. Assignment of Patient Number  
Patients will retain the  unique patient  number that was assigned in study RVT -901-[ADDRESS_723057] be documented by [CONTACT_102]’s dated signature [INVESTIGATOR_2394] a consent form 
along with the dated signature [CONTACT_550415] d iscussion.  
A copy of the signed and dated consent form should be given to the patient before participation 
in the study.  
The initial informed consent form, any subsequent revised written informed consent form, and 
any written information provided to the pa tient must receive institutional review board 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 41 (IRB)/research ethics board (REB)/institutional ethics committee (IEC) approval/favorable 
opi[INVESTIGATOR_19349] .  The patient should be informed in a timely manner if new 
information becomes available that may be relevant to the patient’s willingness to continue 
participation in the study .  The communication of this information will be provided and 
documented via a revised consent form or addendum to the original consent form that captures 
the patient’s date d signature.  
Specifics about a study and the study population will be added to the consent form template at 
the protocol level.  
The informed consent will adhere to IRB/REB/IEC requirements, applicable laws and 
regulations and Sponsor requirements.  
7.6. Inclusio n/Exclusion Criteria  
Prior to randomization in RVT -901-3004, a ll inclusion and exclusion criteria will be reviewed by 
[CONTACT_550395] . 
All inclusion criteria must be met and none of the exclusion criteria may apply .  No eligibility 
waivers will be granted.  
Patients found ineligible during review of inclusion/exclusion will not proceed through the 
randomization  process.  
Compliance with self -administration of Study Treatment in study RV T-901-3003 will be 
calculated based on the tablet/capsule counts recorded in the IxRS  of the Run -In and Treatment 
phase in study RVT -901-3003  (Visits #2 through Visit # 6).   
Laboratory r esults from the Week  [ADDRESS_723058] all medications, if any, taken by [CONTACT_195830] .  
This will include initiation of new medications, or changes to existing/ongoing medicat ions.  
Upon entry into the study, patients will be instructed to report the possible need for any 
prescription or nonprescription medications immediately (and before use) to the Investigator.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 42 7.7.3.  Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_149977]  3 provides a listing of specific restrictions for concomitant therapy use during the study, 
with any necessary washout periods described .  This table provides exam ples of prohibited drug 
categories; however, it is not a comprehensive list of all restricted medications.  
Use of other concomitant therapi[INVESTIGATOR_329878]  7.7.5  are also prohibited if the 
patient’s dose has changed during the RVT -901-3003 study or if the patient plans to initiate or 
change any of these therapi[INVESTIGATOR_226]  (as deemed clinical relevant in the opi[INVESTIGATOR_550381]) . 
If there is a clinical indication for any therapy that is specifically prohibited during the study, 
discontinuation from Study Treatment may be required .  The Investigator should discuss any 
questions regarding this with the medical monitor .  The final decision on any supportive therapy 
rests with the Investigator and/or the patient's primary physician .  However, the decision to 
continue the patient on Study Treatment requires the mutual agreement of the Investigator, the 
Sponsor, and the patient.  
Consult the medical monitor if there is any uncertainty regarding patient use of a particular drug 
or drug class.  
Table  3 Listing of Prohibited Medications  
Class  Examples  Washout Period/Comments  
Anticholinergics  darifenacin, fesoterodine, hyoscyamine, 
oxybutynin, propantheline, solifenacin, 
tolterodine, and trospi[INVESTIGATOR_550382], dicyclomine, propi[INVESTIGATOR_550383]-[ADDRESS_723059] not receive this 
therapy during the study  
a Only the listed example medications (w arfarin, digoxin, lithium, phenytoin, and theophylline)  are prohibited; other 
medications with a narrow therapeutic index (e.g., levothyroxine sodium ) are not prohibited.  
 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723060] an to initiate or change 
any of the following therapi[INVESTIGATOR_550384]  (when the 
change is  deemed clinically relevant by [CONTACT_093]) : 
• Tricyclic antidepressants or combinations, including, but not limited to, amitriptyline, 
imipramine, and doxepin.  
• Alpha -1-antagonists, unless used for BPH treatment, in which case, stable dosing for 
3 months is required.  
• Serotonin and/or norepi[INVESTIGATOR_5608], including, but not limited to, 
fluoxetine, paroxetine, and duloxetine.  
• Alpha -adrenergic agonists, including nonspecific sympathomimetic amines, such as, 
but not limited to, ephedrine, pseudoephedrine, and phenylephrine.  
• Diuretic therapy, including, but not limited to, furosemide and hydrochlorothiazide.  
• Inhale d anticholinergic, including, but not limited to, tiotropi[INVESTIGATOR_329881].  
• Regular use of phosphodiesterase type 5 (PDE 5) inhibitors, including, but not limited 
to, tadalafil, sildenafil, and vardenafil.  
Note :  Occasional use of PDE 5 i nhibitors (e.g., for the treatment of erectile dysfunction) 
is allowed throughout the study.  
Male patients with mild to moderate BPH without evidence of bladder obstruction as determined 
by [CONTACT_329919] a medication for the 
treatment of BPH for at a least [ADDRESS_723061] medications, or other symptomatic treatments or medications .  To 
be eligible for the study, these BPH medication/s  must have been stable  during the RVT -901-
[ADDRESS_723062] be deemed by [CONTACT_11219]/or Medical Monitor as safe to proceed in this study and 
able to co mplete the study per protocol.  
Patients with a history of cerebral vascular accident, transient ischemic attack, unstable angina, 
myocardial infarction, coronary artery interventions (e.g., coronary artery by[CONTACT_550396] [e.g., angioplasty, stent insertion]), or neurovascular 
interventions (e.g., carotid artery stenting) should be on stable medical therapy .  To be eligible 
for the study, these medication/s must have been stable  during the RVT -901-3003 study  and 
antici pated to be stable throughout the extension study , unless approved by [CONTACT_7195] . 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 44 7.8. Patient Voiding Diary  
The Patient Voiding Diary is used by [CONTACT_4317] (via the eDiary or paper Diary) to record the 
frequency of daily OAB symptoms including all micturitions, urgency, incontinence, and main 
reason for incontinence by [CONTACT_329932] a given day and night.  
The Patient Voiding Diary should be completed by [CONTACT_329911] 7 days p rior to the 
Week s 16, 24, 44, and 52  Visits.  
A “Diary Day”  is defined as the time between when the patient gets up for the day each morning 
(i.e., the time the patient got up for the day yesterday to the time the patient got up for the day 
today; approxima tely a 24 -hour period).  
A “Complete Diary Day ” is defined as a Diary Day for which the patient indicates that they 
have recorded all urinations and any leakages that occurred during that Diary Day .  More 
specifically , a “Complete Diary Day” is defined as a  Diary Day that includes input of micturition 
data by [CONTACT_550397] , and  unless a patient indicated “No” to the questions of 
“Did  you record each time you urinated or leaked during this Diary Day” , the Diary Day is  
considered complete.  
7.8.1.  Patient Voiding Diary Training/Re -Training  
All Visits  
The site staff should inquire whether patients had any difficulties with the diary and address any 
questions patients may have .   
Instructions for proper completion of the Patient Voiding Diary should b e re-reviewed, and, if 
available, patients may view an instructional video to reinforce their understanding of Patient 
Voiding Diary instructions.  
Patients will be trained  to enter data immediately following each event  (in real time) and to input 
data from  any “missed” events as soon as they are able .  They will review and confirm that data 
from all events  occurring within the preceding Diary Day (approximately 24 hours ) have been 
entered at a consistent time each morn ing (e.g., upon getting up for the day) . 
7.9. Urine Volume Diary  
Urine volume data are collected separately by [CONTACT_329934], or the paper Urine Volume Chart .  The Urine Volume Chart is a tool routinely used in 
clinical practice and clinical investigation to  assess voiding functions over a 24 -hour period and 
is regarded as a useful instrument in the investigation of patients with voiding symptoms .  Urine 
volume may be collected during any one (1) of the [ADDRESS_723063] ed for ~[ADDRESS_723064] their urine volume passed 
during tha t day .  The Urine Volume collection and Urine Volume Diary completion should be 
performed by [CONTACT_128762] a day that they choose for one (1) complete day of the 7 days prior  to 
the Weeks 16, 24, 44, and 52  Visits .  The definition of a Diary Day and data entry instructions 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 45 will be the same as for the Patient Voiding Diary (i.e., the data should be recorded in real time, 
morning to morning).  
7.9.1.  Urine Volume Collection Training/Re -Training  
At each subsequent visit the site  staff should confirm the patient’s understanding and ability to 
measure a volume of water as practice.  
Patients should be instructed that on the days the paper Urine Volume Chart Diary is completed:  
• Every micturition recorded on the Patient Voiding Diary must have a corresponding 
entry recorded on the Urine Volume Chart  (this is automatically done on the eDiary) . 
• Every entry recorded on the Urine Volume Chart must have a corresponding 
micturition recorded on the Patient Voiding Diary  (this is automatically  done on the 
eDiary) . 
Site staff should reinstruct the patient on Urine Volume collection procedures as needed .  
Instructions for proper completion of the Urine Volume Chart should be re -reviewed, and, if 
available, patients may view an instructional video  to reinforce their understanding of the Urine 
Volume Chart and collection instructions.  
7.9.2.  Dispense Urine Collection and Measurement Supplies  
The urine collection and measurement container (if needed) are reusable and should be rinsed by 
[CONTACT_329935] .  Patients should be reminded to keep the urine collection container  with them during the 
period of time when urine volume is being collected.  
7.10. Reminders for Diary Collection  
The site will phone the patient on approximately the first day and the third (or next business 
days) of the 7 Diary collection days .  Patients will be reminded to enter data immediately 
following each micturition (in real time); they will also be asked to input data from any “missed” 
events  and confirm that data from all micturitions occurring within the preceding [ADDRESS_723065] 
been entered at a consistent time each morning (e.g., upon getting up for the day) .  Patients may 
consent to receive a dditional rem inders via  SMS text to their personal mobile  phone .  In addition 
to visit reminders, t hese diary completion reminders will be sent  the day before each diary 
collection period begins (to remind patients to start diary completion) and two days prior to the 
end of each diary collect window  (to ensure urine volume collection has been completed prior to 
the visit) .   
7.11. Electronic Diary  
The Electronic Diary (eDiary) for this study includes both the Patient Voiding Diary and the 
Urine Volume Diary and  will be implem ented via an eDiary device (provisioned smartphone) .  
Paper diaries will be provided to all patients to be used when necessary .  When a paper diary is 
used, it should be collected at each visit .   
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 46 7.11.1.  eDiary Device Set -Up and Training  
Device Setup/Function Check  
The eDiary device will be set -up by [CONTACT_550398] 12 Visit and dispensed to the Patient .  
At each subsequent visit, site personnel will check that the device is functioning correctly .  
Instructions on how to perform the set -up task will be pro vided by [CONTACT_1034].  
7.11.2.  Device Training/Re -Training  
The site staff should inquire whether patients had any difficulties with the diary and address any 
questions patients may have.  
 
Instructions for proper completion of the eDiary should be re -reviewed, and, if available, patients 
may be asked to view an instructional video to reinforce their understanding of Patient Voiding 
Diary instructions.  
 
Patients will be asked to enter data immediately following each micturition (in real time); they 
will also be asked to input data from any “missed” micturition and confirm that data from all 
micturitions occurring within the preceding [ADDRESS_723066] been entered at a consistent time each 
morning (e.g., upon getting up for the day).  
 
7.12. Patient -Reported Outcomes  
Patients wil l complete paper questionnaires at the site at the start of each required study visit to 
assess patient -perceived symptom relief, symptom bother, and health -related quality of life at the 
study visits .  These include the following questionnaires:  
• Global Im pression Items include Patient Global Impression of Severity (PGI -Severity), 
Patient Global Impression of Control (PGI -Control), Patient Global Impression of 
Frequency (PGI -Frequency), Patient Global Impression of Leakage (PGI -Leakage), and 
Patient Global Impression of Change (PGI -Change) .   
• Overactive Bladder Questionnaire (OAB -q long form [OAB -q LF], 1 -week recall) is a 
multi -item questionnaire that was developed to assess symptom bother and the impact of 
overactive bladder on health -related quality of li fe.  The instrument was developed and 
validated in both continent and incontinent OAB patients, including both men and 
women.  
• Work Productivity and Activity Impairment Questionnaire -Urinary Symptoms (WPAI -
US), version 2.0, is a 6 -item questionnaire that assesses health -related work productivity 
loss due to urinary symptoms with a 1 -week recall period .   
• The EQ -5D health questionnaire is a standardized instrument for use as a measure of 
health outcome [ Rabin , 2014 ].  It is applicable to a wide range of health conditions and 
treatments; it provides a simple descriptive profile and a single index value for health 
status.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723067] -Void Residual 
(PVR) is a concern with antimuscarinic therapy that promotes smooth muscle relaxation by 
[CONTACT_329937] -induced smooth muscle contraction .  If, during contraction, the bladder 
cannot generate enough pressure to overcome the outlet resistance in the urethra, either becau se 
of poor detrusor contractility or profound obstruction (most commonly from BPH), acute urinary 
retention or incomplete emptying of the bladder may result.  
The volume of urine that remains in the bladder after voiding (PVR) is an objective measurement 
that may serve as a proxy for impaired ability to void .  The physician should assess patients with 
an increase in PVR for an adverse event.  
PVR will be performed via ultrasound at the visits indicated in the Schedule of Activities in 
Section  1.1.  All efforts will be made to ensure the same device and operator are used for all 
PVR measurements for individual patients.  
7.14. Physical Examination  
Focused physi cal examinations will include examination of heart, lungs, abdomen  as well as 
any other organ system in which a previous abnormality was noted at Baseline  (in study 
RVT -901-3003)  or relates to a patient complaint of an adverse event.  
7.15. Electrocardiogram  
A single t welve -lead ECG will be performed at the  Week  [ADDRESS_723068] in a semi -recumbent position . 
7.16. Vital Sign s 
Vital signs including bloo d pressure, heart rate, respi[INVESTIGATOR_1487], and temperature (oral or 
tympanic) will be obtained at all visits after patients have rested quietly in a sitting position for 
5 minutes.  
Three blood pressure measurements will be taken in a sitting position and pe rformed on the same 
arm and by [CONTACT_329938], if possible, for each patient throughout the study .  The following 
instructions should be followed:  
• Sitting systolic and diastolic blood pressures will be determined by [CONTACT_85719] 3 replicate 
measurements obtained 1 to 2 minutes apart .  The average of the 3 replicate blood 
pressure measurements will be used for eligibility and safety assessments (not an 
individual value) .   
The same method for assessing temperature should be used at all visits for a particu lar patient.  
Body weight will be measured with patients in street clothing with jacket/coat and shoes 
removed.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 48 7.17. Adverse Event s 
Spontaneously reported adverse events will be recorded at each visit .  The Investigator or site 
staff is responsible for detecting , documenting, and reporting events that meet the definition of 
an adverse event or serious adverse event .  See Section  8 for details on adverse event definitions 
and reporting.  
7.18. Clinical Laboratory Assessments  
Details regarding specific laboratory procedures/assessments to be performed in this study are 
provided below .  The total amount of blood/tissue to be drawn/collected over the course of the 
study (from pre -study to post -study visits), including approximate blood/tissue volumes 
drawn/collected by [CONTACT_329939]  3. 
Please refer to the Schedule of Activities ( Section  1.1) for specific laboratory tests performed at  
each study visit.  
7.18.1.  Chemistry, Hematology, and Urinalysis (Laboratory Safety Evaluations ) 
Laboratory tests for chemistry, hematology, and urinalysis are specified in  Table  4.  Patients do 
not need to fast prior to laboratory safety tests.  
Analysis of hematology and chemistry will be performed by [CONTACT_550399] .  A urine dipstick and urine pregnancy test (for women of childbearing potential)  will be 
performed at the site  (supplied by [CONTACT_2237]) .  A sample for urinalysis (including 
microscopy [RBCs, WBCs, epi[INVESTIGATOR_1663], and bacteria]) AND urine culture will be sent to the 
central laboratory only if the ur ine dipstick tests positive for the presence of leukocytes, nitrites, 
or blood cells .  If a patient reports symptoms that are suggestive of a urinary tract infection at 
any visit, a urine dipstick should be performed and a sample sent for urinalysis and cu lture, as 
needed.  
If all laboratory values are within the normal reference range, the patient may continue to be 
evaluated for study entry .  If one or more values fall outside the normal range, the Investigator 
may either exclude the patient from the study  or investigate further to determine clinical 
relevance .  Please refer to Appendix  2 for an algorithm for assessing out -of-range laboratory 
values . 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 49 Table  4 Laboratory Tests  
Hematology  Chemistry  Urinalysisa Other  
Hematocrit  Albumin  Blood  Serum β -human chorionic 
gonadotropin (β -hCG)b  
Hemoglobin  Alkaline phosphatase  Glucose   
Platelet count  Alanine aminotransferase 
(ALT)  Protein   
WBC (total and 
differential)  Aspartate aminotransferase 
(AST)  Specific gravity   
RBC  Bicarbonate  Microscopic exam, 
(RBCs, WBCs, 
epi[INVESTIGATOR_1663], and 
bacteria)   
 Calcium  pH  
 Chloride  Color   
 Creatininec Urine pregnancy test 
(β-hCG)   
 Glucose (fasting or non -
fasting)    
 Potassium    
 Sodium    
 Total Bilirubin    
 Direct Bilirubind   
 Blood Urea Nitrogen    
 Total Cholesterol    
a. A sample for urinalysis and urine culture will be sent to the central laboratory only if the urine dipstick 
performed at the site tests positive for the presence of leukocytes, nitrites, or blood cells.  
b. Urine β -hCG will be tested for women of childbearing potential only .  If urine β -hCG is positive, a 
serum β -hCG must be performed.  
c. eGFR will be ca lculated and reported by [CONTACT_6626].  
d. If total bilirubin is elevated above the upper limit of normal.  
 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723069] at each study 
visit indicated on the Schedule of Activities ( Section  1.1).  A urine pregnancy test (supplied by 
[CONTACT_2237]) will be performed at the site .  A positive urine β -hCG test must be 
followed up with a serum β -hCG pregnancy test .  A positive pregnancy test prior to 
randomization requires exclusion .  A positive urine β -hCG test after randomization requires 
immediate interruption of Study Treatment until a serum β -hCG is performed and found to be 
negative .  Patient must be discontinued from the study and followed if pregnancy is confirmed 
by a positive serum β -hCG.  
7.19. IxRS Randomization to Study Treatment  
Assignm ent of patients to double -blind Study Treatment in this study is described in Section  4.1 
and Section  6.3.  The Study Treatment assignments will b e managed/recorded via the IxRS . 
7.20. Dispense Double -Blind  Study Treatment  
At the Week  12, 16, 24, 36 and 44 Visits, double -blind Study Treatment will be dispensed to 
patients, as described in Section  6, and according to their randomized treatment assigned per 
IxRS. 
7.21. Study Treatment Return/Accountability Review  
Patients should bring all unused study drug to each study visit .  A complete tablet/capsule count 
will be performed, and results will be recorded as the primary source of patient Study Treatment 
compliance .  Tablet/capsule counts will also be recorded in the IxRS .  All patients should be 
reinstructed regarding dosing compliance during study visits .  The authorized study personnel 
conducting the re -education must document the process in the patient’s source rec ords.  
7.22. Follow -up Visit  
The Follow -up Visit should be performed 28 days after the patient’s last dose of Study 
Treatment to collect information about any serious adverse events that occurred during this 
period .  For a patient who discontinues Study Treatment  early, the Follow -up Visit should occur 
[ADDRESS_723070] dose of Study Treatment .  However, if the  discontinuation visit occurs 
≥ 28 days after the patient’s last dose of Study Treatment, that visit will serve as the Follow -up 
Visit .  Safety labs ma y be collected for the evaluation of adverse experiences during 
discontinuation at the discretion of the Investigator.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 51 8. SAFETY CONSIDER ATIONS  
Study assessments of safety include adverse events, physical examinations, vital signs (and 
weight), and clinical l aboratory tests.  
8.1. Definition of an Adverse Event  
An adverse event is any untoward medical occurrence in a patient or clinical investigation 
patient, temporally associated with the use of a medicinal product, whether or not considered 
related to the medicina l product.  
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use 
of a medicinal product or protocol -specified procedure,  whether or not considered related to the 
medicinal product or protocol -specified procedure .  Any worsening (i.e., any clinically 
significant adverse change in frequency and/or intensity) of a preexisting condition that is 
temporally associated with the us e of the Sponsor’s product, is also an adverse event.  
Events meeting the definition of an adverse event include : 
• A worsening, excluding minor fluctuations, in the nature, severity, frequency, or duration 
of a pre -existing condition;  
• A new condition detecte d or diagnosed after investigational product administration even 
though it may have been present prior to the start of the study;  
• Injury or accidents :  If a medical condition is known to have caused the injury or 
accident, the medical condition and the acc ident should be reported as 2 separate medical 
events (e.g., for a fall secondary to dizziness, both “dizziness” and “fall” should be 
recorded separately);  
• An investigational abnormality (e.g., laboratory parameter, vital sign, ECG) only if the 
abnormalit y is considered clinically significant by [CONTACT_550400]:  
− Induces clinical signs or symptoms;  
− Requires active intervention;  
− Requires interruption or discontinuation of Study Treatment .   
• Signs, symptoms, o r the clinical sequelae of a suspected interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concomitant medication.  
• Events that do not  meet the definition of an adverse event include:  
• The disease/disorder being studied, or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the patient’s 
condition;  
• Medical or surgical procedure (e.g., endoscopy, appendectomy) should be entered  into 
the electronic case report form (eCRF) .  If not planned prior to signing the informed 
consent, the condition that leads to the procedure is reported as an adverse or serious 
event, as appropriate .  Periodic procedures for routine maintenance of a med ical device 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 52 should not be considered associated with an adverse event (e.g., expected change of a 
stent);  
• Situations where an untoward medical occurrence did not occur (e.g., planned 
hospi[INVESTIGATOR_34096], with elective defined as known  or planned at the 
time of signing of the informed consent; social and/or convenience admission to a 
hospi[INVESTIGATOR_307]);  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
Adverse events that occur during the study should be evaluated by [CONTACT_329942], as described in Section  8.4 and 
Section  8.5.  Epi[INVESTIGATOR_329886], such as vomiting, or those that occur repeatedly over a 
period of co nsecutive days are “intermittent” .  All other events are “continuous” .  Additional 
information on detecting, documenting, and reporting adverse events and serious adverse events 
are provided below .  No toxicity -related dose reductions of Study Treatment are permitted; 
however, Study Treatment can be held for a period of up to 21 days for evaluation and treatment 
of an adverse event .  The Study Treatment may be restarted if deemed safe for the patient by [CONTACT_3786].  
8.2. Definition of a Serious Adverse Ev ent 
If an event is not an adverse event per Section  8.1, then it cannot be a serious adverse event if 
serious conditions are met (e.g., hospi[INVESTIGATOR_446388]/symptoms of the disease under study, 
death due to progression of disease, etc.) .  A serious adverse event is any untoward medical 
occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
c. NOTE :  The term 'life -threatening' in the de finition of 'serious' refers to an event in 
which the patient was at risk of death at the time of the event .  It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.  
d. Requires hospi[INVESTIGATOR_17127] e xisting hospi[INVESTIGATOR_059]  
e. NOTE :  In general, hospi[INVESTIGATOR_329887] 
(usually involving at least an overnight stay) at the hospi[INVESTIGATOR_1083]/or treatment that would not have been appropriate i n the physician’s 
office or out -patient setting .  Complications that occur during hospi[INVESTIGATOR_329888] .  If a complication prolongs hospi[INVESTIGATOR_40030], the event is serious .  When in doubt as to whether “ho spi[INVESTIGATOR_059]” occurred 
or was necessary, the adverse event should be considered serious.  
f. Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
g. Results in disability/incapacity  
h. NOTE :  The term disability means a substantial disruption of a person’s ability to 
conduct normal life functions .  This definition is not intended to include experiences 
of relatively minor medical significance such as uncomplicated headache, nausea, 
vomiting, di arrhea, influenza, and accidental trauma (e.g. , sprained ankle) which may 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 53 interfere or prevent everyday life functions but do not constitute a substantial 
disruption.  
i. Is a congenital anomaly/birth defect  
j. Medical or scientific judgment should be exercised i n deciding whether reporting is 
appropriate in other situations, such as important medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_550385] .  These should also be considered serious .  
Examples of such events are invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, bl ood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.  
8.3. Adverse Event  Reporting  
The Investigator or site staff is responsible for detecting, documenting, and reporting events that 
meet the definition of an adverse event or serious adverse event.  
The reporting of serious adverse events by [CONTACT_1034] (Urovant Sciences GmbH) to regulatory 
authorities is a requirement and each authority has a timetable for reporting these events based 
upon esta blished criteria .  Likewise, it is the responsibility of the Investigator to report serious 
adverse events to their local IRB, REB, or IEC, as required by [CONTACT_9918]/REB/IEC 
requirements.  
Care will be taken not to introduce bias when detecting adverse  events and/or serious adverse 
events .  Open -ended and non -leading verbal questioning of the patient is the preferred method to 
inquire about adverse event occurrence .  Appropriate questions include:  
• • “How are you feeling?”  
• • “Have you had any (other) med ical problems since your last visit/contact?”  
• • “Have you taken any new medicines, other than those provided in this study, since 
your last visit/contact?  
The patient’s diary entries and responses to questionnaires used in the study will not be used as a 
primary means to collect adverse events however, they should be reviewed by [CONTACT_329943] .  Should the Investigator or site staff become aware of a 
potential adverse event through the information collected with these instr uments, proper follow -
up with the patient for medical evaluation should be undertaken .  Through this follow -up, if it is 
determined that an adverse event not previously reported has been identified, normal reporting 
requirements should be applied.  
All pati ents who experience an adverse event will be evaluated at appropriate time intervals and 
followed until the event resolves, becomes stable or chronic, or the patient is deemed lost to 
follow -up.  At the conclusion of the study, the Investigator and medical  monitor will assess 
unresolved adverse events and determine if additional/continued follow -up is warranted.  
All adverse events, whether related to the Study Treatment or not, must be fully and completely 
documented on the adverse event case report form an d in the patient’s source documents .  In 
addition, any adverse event resulting in permanent treatment discontinuation must be recorded 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 54 on the appropriate case report form as well as documented in the patient’s source documents .  
Adverse event terms should include a diagnosis, as available, in preference to listing the 
individual signs and symptoms .  If the diagnosis is not known, the Investigator should record 
each sign and symptom as an individual adverse event.  
Reporting for overdose and for pregnancy in the patient or patient’s partner will be reported as 
described in Section  8.3.[ADDRESS_723071] be reported in the eCRF  within 24 hours of the study site 
personnel’s knowledge of the event , regardless of the Investigator assessment of the 
relationship of the event to Study Treatment.  
The event term, start date, severity, and initial causality assessment must be entered in the 
Adve rse Event eCRF page and the event must be marked as “Serious” .  This will activate 
additional assessment fields including “action taken with study drug”, “seriousness criteria”, and 
“brief description” which should be completed as soon as information is av ailable.   Marking the 
event as “serious” will automatically send required notifications for Sponsor review.  
The initial serious adverse event report should include:  
• The date of the report;  
• A description of the serious adverse event (event term, seriousness  of the event, date 
of onset, intensity); and  
• Causal relationship to the Study Treatment.  
A discharge summary should be provided for all hospi[INVESTIGATOR_602] .  If the patient died, the report 
should include the cause of death as the event term (with death as t he outcome) and whether the 
event leading to death was related to Study Treatment, as well as the autopsy findings, if 
available.  
Do not delay reporting a suspected serious adverse event to obtain additional information .  Any 
additional information, if col lected, can be reported as a follow -up to the initial report.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723072] be contact[CONTACT_329944].  
An overdose is defined as a known deliberate or accidental administration of Study Treatment, to 
or by a study patient, at a dose above that assigned to that individual patient acco rding to the 
study protocol.  
For this study, any dose of > 2 tablets and/or > 2 capsules of blinded Study Treatment within a 
24-hour window is an overdose .  There is no known antidote for an overdose.  
In the event of an overdose, the Investigator or treati ng physician should:  
• Contact [CONTACT_10990];  
• Closely monitor the patient for adverse events and laboratory abnormalities;  
• Report all overdose  that result in an  adverse event within 24 hours of awareness by 
[CONTACT_3452], using a serious adverse event form according to  Section  8.3.2 , whether 
or not the overdose is associated with an adverse event;  
• Overdose events that do not result in an adverse event will be reported as a protocol 
deviation in the eCRF ; 
• If possible, obtain a plasma sample for pharmacokinetic  analysis within [ADDRESS_723073] dose of Study Treatment if requested by [CONTACT_7195] 
(determined on a case-by-case basis);  
• Document the quantity of the excess dose as well as the duration of the overdosing in 
the eCRF.  
The medical monitor, in consultation with the Investigator, will make decisions regarding patient 
status and potential dose interruptions, based on the clinical evaluation of the patient.  
8.4. Assigning Causal Relationship to Study Treatment  
The reasonable possibility of the relationship of an adverse event to Study Treatment is to be 
assessed with careful medical consideration at the time of eval uation of an adverse event .  The 
following definitions are to be used for the relationship of the adverse event to Study Treatment:  
• Probably related :  A clinical event, including laboratory test abnormality, with a 
reasonable time sequence to administratio n of the drug, unlikely attributed to 
concurrent disease or other drugs or chemicals, or that follows a clinically reasonable 
response on re -administration (re -challenge) or withdrawal (de -challenge).  
• Possibly related :  A clinical event, including laborato ry test abnormality, with a 
reasonable time sequence to administration of the drug but that could also be 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 56 explained by [CONTACT_9153] .  Information on drug 
withdrawal may be lacking or unclear.  
• Not related :  A clinical event , including laboratory test abnormality, with a temporal 
relationship to drug administration that makes a causal relationship improbable and/or 
in which other drugs, chemicals, or underlying disease provide a plausible 
explanation.  
All adverse events, whet her related to Study Treatment or not, must be fully and completely 
documented on the adverse event page of the eCRF  and in the patient’s clinical record .  In the 
event a patient is withdrawn from the study because of an adverse event, the primary reason for 
withdrawal (i.e., due to an adverse event) must be recorded on the eCRF  as such.  
8.5. Assigning Severity Rating for Adverse Events  
Severity describes the inte nsity of a specific event (as in mild, moderate, or severe myocardial 
infarction); the event itself, however, may be of relatively minor medical significance, such as a 
severe headache .  This is not the same as “serious,” which is based on patient/event ou tcome or 
action taken.  
The Investigator must determine the severity of each adverse event according to the criteria in 
Table  5. 
Table  5 Criteria for Determining the Grade/Severity of Adverse Event Terms  
Grade Criteria  
1/Mild  Asymptomatic or mild symptoms, clinical or diagnostic 
observations only; intervention not indicated  
2/Moderate  Minimal, local, or noninvasive intervention indicated; limiting age -
appropriate instrumental activities of daily living  
3/Severe or medically significant  Not immediately life -threatening; hospi[INVESTIGATOR_24599]; disabling; limiting self -care activi ties of 
daily living  
4/Life -threatening  Life threatening consequences; urgent intervention indicated  
5/Death  Death related to adverse event  
 
Adverse event severity should be recorded in the appropriate section of the adverse event case 
report form and in the patient’s source documents.  
8.6. Adverse Events of Clinical Interest  
Selected non -serious and serious adverse events will be reported as Adverse Events of Clinical 
Interest (AECI) and must be reported within 24  hours of the study site personnel’s knowled ge 
of the event  as an AECI by [CONTACT_329945] .  Additional information requested should be provided as directed in 
the eCRF Completion Guidelines (eCCGs).  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723074] for this study include:  
• Potential Major Adverse Cardiac and Cerebrovascular Events (MACCE) , which will be 
adjudicated by [CONTACT_550401] (CAC) 
into the following categories according to the definitions in the CAC Charter : 
− Death or any event with fatal outcome  
− Myocardial infarction  / Heart Attack  
− Cerebrovascular Accident / Stroke  
− Hospi[INVESTIGATOR_329890] / Chest Pain 
− Hospi[INVESTIGATOR_85060]  
− Coronary revascularization  / Angioplasty / Stent  
• Hypertension : 
An adverse event of hypertension should be reported and will be an AECI as follows:  
− For patients without hypertension (average SBP  <140  mmHg, DBP  <90 mmHg)  
at baseline, at two consecutive visits, the  average of three systolic blood pressure 
(SBP)  ≥140  mmHg or diastolic blood pressure (DBP)  ≥90 mmH g (or both ); at 
2 consecutive visits in patients who were not hypertensive at baseline; or,  
− For pati ents with hypertension at baseline, an increase compared to baseline at 
2 consecutive visits  in the a verage of three SBP by ≥20 mmHg OR DBP 
by ≥10 mmHg ;  
− Initiation of, or increase in dose of, medication for treatment of hypertension in 
any patient.  
• Adverse events consistent with orthostatic hypotension as confirmed by [CONTACT_329948].  
• Adverse events suggestive of cystitis or urinary tract infection . 
• Elevated AST or ALT lab value  requiring that study drug be temporarily withheld or 
permanently discontinued (see Section  8.6.1  and Section  8.6.2 ). 
8.6.1.  Criteria for Temporary Withholding of Study Treatment  in Association with 
Liver Test Abnormalities  
Elevated liver enzymes or bilirubin sufficient to require withholding study medi cation must be 
reported within 24  hours of the study site personnel’s knowledge of the event  using AECI 
specific CRFs/forms/worksheets provided for the study.  
Hepatic enzymes will be monitored in accordance with FDA drug -induced liver injury guidelines 
[FDA , 2009 ]. 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723075] abnormalities develop, Study Treatment should be withheld 
immediately with appropriate clinical follow -up (incl uding repeat laboratory tests, until a 
patient’s laboratory profile has returned to normal/baseline status), and the event reported as a 
serious adverse event:  
• ALT or AST > [ADDRESS_723076]; or  
• ALT or AST > [ADDRESS_723077] and persists for more than 2 weeks; or  
• ALT or AST > [ADDRESS_723078] and total bilirubin > [ADDRESS_723079] or international normalized 
ratio (INR) >1.5  
• ALT or AST > [ADDRESS_723080] with appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash and/or eosinophilia (>5%).  
Rechallenge may be consi dered if an alternative cause for the abnormal liver tests (ALT, AST, 
total bilirubin) is discovered and the laboratory abnormalities resolve to normal or baseline 
values .  The Investigator and Sponsor must discuss and agree with any decision to rechallenge.  
Rechallenge should not occur when the etiology of the liver test abnormalities is considered 
possibly drug induced.  
8.6.2.  Criteria for Permanent Discontinuation of Study Treatment  in Association with 
Liver Test Abnormalities  
Study treatment should b e discontinued permanently if all of the following 4 criteria are met 
(i.e., potential severe drug -induced liver injury/Hy’s law case):  
1. Total bilirubin increases to > [ADDRESS_723081] or INR > 1.5; AND  
2. AST or ALT increases to ≥ [ADDRESS_723082]; AND  
3. Alkaline phosphatase val ue does not reach [ADDRESS_723083]; AND  
4. No alternative cause explains the combination of the above laboratory abnormalities; 
important alternative causes include, but are not limited to the following:  
• Hepatobiliary tract disease;  
• Viral hepatitis (e.g., hepatitis A/ B/C/D/E, Epstein -Barr virus);  
• Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and dietary 
supplements, plants, and mushrooms;  
• Alcoholic hepatitis;  
• Non-alcoholic steatohepatitis; or  
• Autoimmune hepatitis.  
If an alternative cause for hepatotoxicity is identified, then it should be determined (based on the 
severity of the hepatotoxicity or event) whether Study Treatment should be withheld or 
permanently discontinued as appropriate for the safety of the patient.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723084] the patient return for an 
Early Withdrawal Visit ( Week  52 Visit activi ties).  The Investigator must inform the patient of 
their right to receive treatment information .  If the patient chooses to receive unblinded treatment 
information, the individual blind should be broken and the treatment assignment provided to the 
patient .  The study team will remain blinded to the patient’s treatment assignment.  
In the case of a pregnant patient, if she agrees, the Investigator should notify the patient’s 
primary care physician of the pregnancy and provide details of the patient’s partici pation in the 
study and treatment (blinded or unblinded, as applicable).  
In the case of a male patient with a pregnant partner, if the patient agrees, the patient’s pregnant 
partner should be notified and requested to sign a Release of Information form, pe rmitting 
transfer of information regarding the pregnancy and outcome to the Sponsor.  
A pregnancy is to be reported to the Sponsor within [ADDRESS_723085] menstruation, 
estimated conception date, pregnancy  result, neonatal data, etc .  should be included in this 
information, as available.  
The Investigator will follow the medical status of the mother, the pregnancy, as well as the 
outcome of the infant at birth, and will report the outcome to the Sponsor.  
8.8. Benefit/Risk Assessment  
Patients may not expect to receive direct benefit from treatment during participation, as this 
study is designed to provide information about the safety and effectiveness of an investigational 
medicine compared to placebo .  Some pat ients will receive tolterodine, an approved medication 
for treating overactive bladder with symptoms of urinary frequency, urgency, and leakage.  
Additional details about vibegron may be found in the current vibegron Investigator’s Brochure 
(IB) and Informe d Consent documents.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 60 9. STATISTICAL CONSIDER ATIONS  
This section contains a brief summary of the statistical analyses for this study ; full details shall 
be provided in the Statistical Analysis Plan.  
9.1. Responsibility for Analyses/In -House  Blinding  
The statistical  analysis of the data obtained from this study  will be the responsibility of the 
designee of the Sponsor.  
The study will be conducted as a double -blind , Sponsor open (partially unblinded ) study  as 
described in Section  6.4. 
At the end of the study (including the period of 28 days follow -up), the official, final database 
will be frozen and unblinded after medical/scientific review has been performed, and data have 
been declared final and complete .  A Statistical Analysis Plan will be approved prior to data 
being unblinded .  A clinical study report will be prepared after all patient s complete the study . 
9.2. Hypotheses  
9.2.1.  Primary Objective and Hypotheses  
The primary objective will be to demonstrate the long -term safety  of vibegron 75  mg in patients 
with symptoms of OAB .  There is no for mal statistical primary endpoint hypothesis .  Rather, 
incidence of treatment -emergent AEs by [CONTACT_550402] -901-3004 . 
9.2.2.  Secondary Objectives  
There are no formal sta tistical hypotheses for this trial .  Below are the secondary efficacy 
objectives of this trial.  
(1) Objective :  To evaluate the effica cy of vibegron in reducing the average number of 
daily micturitions from baseline at Week  52 in all patients with OAB.  
(2) Objective :  To evaluate the efficacy of vibegron in reducing the average number of 
daily UUI epi[INVESTIGATOR_550386]  52 in all patients with OAB.  
(3) Objective :  To evaluate the efficacy of vibegron in reducing the average number of 
urgency epi[INVESTIGATOR_550386]  52 in all patients with OAB.  
(6) Objective :  To evaluate the efficacy of vibegron in reducing the average number of 
total urinary incontinence epi[INVESTIGATOR_550386]  52 in all patients with 
OAB Wet.  

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 61 9.3. Analysis  Endpoints  
The descriptions of the endpoints and time points at which they are measured are described in 
Section  3 and Section  1.1 (Schedule of Activities), respectively.  
No formal statistical comparisons of vibegron vs. tolterodine are planned .  Any statistical  
analyses will be considered descriptive.  
9.3.1.  Efficacy  Endpoints  
For the purpose of this study, the number of micturitions  will be defined as the number of times a 
patient has voided in the toilet as indicated on the Voiding Diary .  Average daily micturitions are 
calculated using the daily entries in the Voiding Diary, which is completed prior to each study 
visit.  Average da ily number of micturitions will be calculated as the total number of micturitions 
that occur on a Complete Diary Day  divided by [CONTACT_550403] .  A “Complete Diary Day ” is defined as a Diary Day that includes input of  
micturition data  by [CONTACT_550397].   Unless a patient indicated “No” to the 
questions of “Did you record each time you urinated or leaked during this Diary Day ”, the Diary 
Day is  considered complete .  Baseline is defined as the average numb er of micturitions occurring 
during the week of Run -in prior to the Baseline Visit  in study RVT -901-3003 .  If data from the 
study RVT -901-3003 Run-in are not available for a patient, data collected during Screening will 
serve as the baseline . 
The number of  UUI epi[INVESTIGATOR_329899] a patient has checked "urge" 
as the reason for accidental urine leakage .  Average daily urge urinary incontinence epi[INVESTIGATOR_550387] .  The urge urinary incontinence endpoint will be analyzed using only OAB Wet 
patients.  
Secondary  Endpoints:  
• Change from baseline (CFB) at Week  52 in average number of micturitions per 
24 hours in all OAB patients  
• CFB at Week  52 in  average number of urge urinary incontinence (UUI) epi[INVESTIGATOR_11629] 
24hours in OAB Wet patients  

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 62 • CFB at Week  52 in average number of urgency epi[INVESTIGATOR_1841] (need to urinate 
immediately) over 24 hours in all OAB patients  
• CFB at Week  52 in average number of total urina ry incontinence epi[INVESTIGATOR_17767] 24 
hours in OAB Wet patients  
Exploratory Endpoints:  

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 63 9.3.2.  Safety  Endpoints  
Safety and tolerability will be assessed via clinical re view of all relevant safety parameters 
including clinical adverse event s, clinical laborator ies, vital signs , and physical examinations  that 
occurred during the respective study period.  
9.4. Analysis  Populations  
9.4.1.  Efficacy Analysis  Populations  
The Full Analysis Set Extension  (FAS -Ext) population will serve as the population for the 
analysis of efficacy data in this study .  Since the endpoints related to incontinence would only 
apply to patient s who meet the definition of incontinence at study  entry, it is necessary to have a 
separate FAS definition with an additional criterion to define the analysis population for 
incontinence endpoints.  
The following FAS populations are defined in the study:  
• Full analysis set  extension  (FAS -Ext):  all OAB patients who took at least one dose of 
double -blind Study Treatment  in the current study  and have at least one evaluable 
change from baseline  micturition measurement  in this study  
• Full analysis set  extension  for incontinence (FAS -Ext-I):  all OAB Wet patient s who 
took at least one dose of double -blind Study Treatment  in the current study  and have 
at least one evaluable change from baseline  urge urinary incontinence  measurement  
in this study  
The Per -Protocol extension population (PP -Ext) and Per -Protocol extens ion population for 
incontinence (PP -Ext-I) exclude patient s due to important deviations from the protocol that may 
substantially affect the results of the efficacy endpoints .  A supportive analysis using the Per -

Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 64 Protocol populations will be performed for the 4 key secondary efficacy endpoints .  The final 
determination on protocol violations, and thereby [CONTACT_329950] -Protocol 
population, will be made prior to the unblinding of the database and will be  documented in a 
separate memo.  
Patients will be included in the treatment group to which they are randomized  to for the analysis 
of efficacy data using the F ull Analysis Set and Per -Protocol populations .  Efficacy endpoints 
will be descriptively summarize d by [CONTACT_550404] -901-3003 
and study RVT -901-3004 .  This means there will be 4 treatment groups  including vibegron  for 
52 weeks, tolterodine  for 52 weeks, vibegron for 40  weeks , and tolterodine for 40  weeks.  
9.4.2.  Safety Analysi s Populations  
The Safety Analysis  (SAF) population will be used for the analysis of safety data in this study .  
The SAF population consists of all patient s who received at least one dose of Study Treatment  in 
this study .  Patient s will be included in the treatment group corresponding to the Study Treatment  
they actually received for the analysis of safety data using the SAF population .  For most 
patient s, this will be the treatment group to which they were randomized .  Patient s who take 
incorrect Study Treatment  for the entire Treatment Period  will be included in the treatment group 
corresponding to the Study Treatment  actually  received.   Safety endpoints will be descriptively 
summarized based on treatment in study RVT -901-3004 .  This means there will be 2 treatment 
groups  including vibegron (52 weeks and 40 weeks combined) and tolterodine (52 weeks and 
40 weeks combined).  
At least one laboratory or vital sign measurement obtained subsequent to at least one dose of 
Study Treatment  is required for inclusion in the analysis of each specific parameter .  To assess 
change from baseline , a Baseline  measurement is also required.  
No imputation will be performed for missing safety data.  Baseline will be defined as the last 
non- missing value before double -blind  treatment  in study RVT -901-3003 .  Further inclusion of  
data from RVT -901-3003 in the reporting of this study  will be described in the SAP.  
9.5. Statistical  Methods  
9.5.1.  Statistical Methods f or Efficacy  Analyses  
Secondary  Endpoints :  Efficacy  
Statistical analysis of efficacy endpoints  will be for descriptive purposes only .  Baseline will be 
the RVT -901-3003 baseline.   Further inclusion of data from RVT -901-3003 in the reporting of 
this study w ill be described in the SAP.  
For the analysis of continuous change from baseline  endpoints  (e.g., change from baseline in 
average number of daily micturitions , change from baseline in average number of daily urge 
urinary incontinence  epi[INVESTIGATOR_1841] , change from baseline  in average number of urgency epi[INVESTIGATOR_1841] , and 
change from baseline  in average number of total incontinence epi[INVESTIGATOR_1841] ), a mixed model for 
repeated measure (MMRM) with restricted maximum likelihood estimation will be used .  This 
model corrects for dropo ut and accounts for the fact that measurements taken on the same patient  
over time tend to be correlated, by [CONTACT_550405] s within the same 
covariate set to derive an estimate of the treatment effect for a dropout -free populati on.  The 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 65 analysis model for each efficacy endpoint will include terms for treatment, visit, baseline 
stratification factors  (only those that were  statistically significant in RVT -901-3003 will be 
included in the models) , baseline score, and interaction of visit by [CONTACT_3148].   Only patients on 
active treatment in both RVT -901-3003 and RVT -901-3004 will be included in the model.  
Adjusted  means and 95% confidence intervals will be presented for each visit and each treatment 
group.   No p -values and no treatment  differences will be presented.  
An unstructured covariance matrix will be used to model the correlation among repeated 
measurements .  The Kenward -Roger adjustment will be used with restricted (or residual) 
maximum likelihood (REML) to make proper statistic al inference .  If the unstructured 
covariance model fails to converge with the default Newton -Raphson algorithm, the Fisher 
scoring algorithm or other appropriate methods can be used to provide initial values of the 
covariance parameters .  In the rare even t that none of the above methods yield convergence, a 
structured covariance will be used to model the correlation among repeated measurements.  
9.5.2.  Statistical Methods for Safety  Analyses  
Safety analyses will be conducted using the safety population and summari zed by [CONTACT_550406] .  The treatment -emergent period will be defined as the period of time from the 
first dose date of the double blinded Study Treatment  in this study through [ADDRESS_723086] of chemistry, he matology, and urinalysis data .  Only data collected 
by [CONTACT_550407].  
Vital signs parameters, including temperature, will be listed and summarized by [CONTACT_765].  
9.6. Multiplicity  
All efficacy endpoints will be considered descrip tive and no multiplicity adjustments will be 
performed for these endpoints . 
9.7. Sample Size Determination  
Five hundred (500) patients rolling over from study RVT -901-3003 , in addition to other long -
term safety data with vibegron, is sufficient  to characterize the long -term safety profile of 
vibegron 75 mg once daily and s atisfies the ICH guidance for 1 -year exposure.  
9.8. Interim  Analyses  
There is no planned interim analysis for efficacy.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 66 10. STUDY GOVERNANCE CON SIDERATIONS  
10.1. Financial Disclosure  
Financial disclosure requirements are outlined by [CONTACT_329956] 21, 
Part 54 (21 CFR 54), Financial Disclosure by [CONTACT_6230] .  It is the Sponsor's 
responsibility to determine, based on these regulations, whether a requ est for financial disclosure 
information is required .  It is the Investigator's and Sub -Investigator's responsibility to comply 
with any such request.  
This is a “covered clinical study”, defined under 21 CFR 54 as “any study of a drug or device in 
humans s ubmitted in a marketing application or reclassification petition patient to this part that 
the applicant or FDA relies on to establish that the product is effective (including studies that 
show equivalence to an effective product) or any study in which a s ingle Investigator makes a 
significant contribution to the demonstration of safety.”  As such, all Investigators and Sub -
Investigators must provide documentation of their financial interest or arrangements with the 
Sponsor, or proprietary interests in the drug being studied .  This documentation must be provided 
before participation of the Investigator and any Sub -Investigator .  The Investigator and Sub -
Investigator agree to notify the Sponsor of any change in reportable interests during the study 
and for 1 year following completion of the study.  
10.2. Data Management  
Patient data will be entered into a Sponsor -approved electronic database and combined with data 
provided from other sources in validated datasets then transmitted electronically to the Sponsor 
or desi gnee.  
Management of clinical data will be performed in accordance with applicable Sponsor -approved 
standards and data cleaning procedures to ensure the integrity of the data (e.g., errors will be 
corrected and inconsistencies clarified).  
Adverse events and  concomitant medications terms will be coded using the most current versions 
of the MedDRA (i.e., 20.0 or higher) and the World Health Organization Drug Dictionary 
Enhanced (WHO -DDE), respectively.  
The Investigator will retain original source documents and  the Sponsor will receive eCRF -
required data as electronic datasets .  Patient initials will not be collected or transmitted to the 
Sponsor.  
10.3. Monitoring  
This study will be monitored by [CONTACT_1034] (or designee) in accordance with current GCP 
regulations .  By [CONTACT_12570], the Investigator grants permission to the Sponsor (or 
designee) and appropriate regulatory authorities to conduct on -site monitoring of all appropriate 
study documentation .  In order to verify the accuracy of data collected in the e CRF, the monitor 
will require direct access to original source documents (e.g., patient records, patient charts, and 
laboratory reports).  
During the review of these documents, the anonymity of the patient will be respected with strict 
adherence to professi onal standards of confidentiality .  A study monitor will contact [CONTACT_550408] -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723087] the various 
records of the study .  It will be the study monitor’s responsibility to insp ect the eCRF at regular 
intervals throughout the study, to verify the adherence to the protocol and the completeness, 
correctness, and accuracy of all eCRF entries, and to meet with the Investigator to discuss study 
progress and compliance with the protoco l and GCP .  The study monitor should have access to 
laboratory test results and any other source records and data needed to verify the entries on the 
eCRF .  The Investigator agrees to cooperate with the study monitor to ensure that any problems 
detected in  the course of these monitoring visits are resolved.  
10.4. Auditing or Inspections  
Representatives of regulatory authorities, health authorities, the Sponsor, or IRB/REB/IEC’s may 
conduct inspections or audits of the clinical study .  If the Investigator is notified of an inspection 
by a regulatory authority, the Investigator agrees to notify the Sponsor’s medical monitor 
immediately .  By [CONTACT_12570], t he Investigator agrees to provide to appropriately 
qualified personnel from such groups, access to  records, facilities, and personnel for the effective 
conduct of any inspection or audit.  
10.5. Study Oversight Committees  
10.5.1.  Clinical Adjudication Committee  
As noted in Section  8.6, MACCE event diagnosis will be adjudicated by [CONTACT_550409].  
10.5.2.  Steering  Committee  
A Steering Committee may be formed, if deemed necessary .  If formed, the committee will be 
comprised of both Sponsor and non -Sponsor scientific experts who will participate in the design, 
conduct, analyses, and publication of the study .  Steering Committee members will remain 
blinded to patients’ treatment assignments and all unblinded data until the database is officially 
locked and unblinded.  
10.6. Protocol Modifications  
Protocol modifications, except those intended to reduce immediate risk to patients, may be made 
only by [CONTACT_1034] .  All protocol modifications must be submitted to the IRB/REB/IEC in 
accordance with local requirem ents.  Approval must be obtained before changes can be 
implemented .  The Investigator must not deviate from the protocol without first obtaining 
approval from the Sponsor and the IRB/REB/IEC, if required .  In medical emergencies, the 
Investigator will use medical judgment and will remove the patient from immediate hazard, then 
notify the Sponsor (or designee) and the IRB/REB/IEC immediately regarding the type of 
emergency and the course of action taken .  The Investigator must notify the Sponsor (or 
designee ) of any inadvertent protocol deviations upon their discovery, and document the 
deviations appropriately in the study files.  
When a protocol amendment substantially alters the study design or the potential risks or burden 
to patients, the informed consent form will be amended and approved by [CONTACT_1201]/REB/IEC, and 
all patients on treatment will again provide informed consent.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 68 10.7. Study Discontinuation  
The Sponsor reserves the right to terminate the study at any time .  Should this be necessary, the 
Sponsor will ar range discontinuation procedures and notify the appropriate regulatory 
authority(ies) and IRB/REB/IEC .  In terminating the study, the Sponsor and the Investigator will 
assure that adequate consideration is given to the protection of the study participants’  interests.  
10.8. Publications  
After conclusion of the study and without prior written approval from the Sponsor, Investigators 
in this study may communicate, orally present, or publish in scientific journals or other scholarly 
media only after the following conditions have been met:  
• The results of the study in their entirety have been publicly disclosed by [CONTACT_550410], manuscript, or presentation form; or  
• The study has been completed at all study sites for at least 5 year s. 
No such communication, presentation, or publication will include Urovant Sciences GmbH 
confidential information (see Section  10.9.5 ). 
The Inves tigator will submit to the Sponsor any proposed publication or presentation along with 
the respective target scientific journal or presentation forum at least 30 days before submission of 
the publication or presentation .  The Investigator will comply with Sponsor requests to delete 
references to its confidential information (other than the study results) in any paper or 
presentation and agrees to withhold publication or presentation for an additional 60 days in order 
to obtain patent protection if deemed ne cessary.  
10.9. Investigator -Specific Responsibilities  
10.9.1.  Compliance with Regulations and Ethical Standards  
The Investigator will ensure that this study is conducted in accordance with the principles of the 
“Declaration of Helsinki” (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and South 
Africa), ICH guidelines, or with the laws and regulations of the country in which the research is 
conducted, whichever affords the greater protection to the study participant .  For studies 
conducted under a [LOCATION_002] invest igational new drug application, the Investigator will 
ensure that the basic principles of GCP, as outlined in 21 Code of Federal Regulations 
(CFR  312), subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, part 50, 1998, 
and 21  CFR, part 56,  1998, are adhered to .  These standards are consistent with the requirements 
of the European Community Directive 2001/20/EC.  
The Investigator will also comply with financial disclosure requirements as described in 
Section  10.1. 
10.9.2.  Protocol Compliance  
The Investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations de scribed in this protocol.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723088]/Independent Ethics Committee Requirements  
The protocol, protocol amendments, informed consent form, IB, and any other relevant 
materials, including accompanying material to be provided to the patient (e. g., advertisements, 
patient information sheets, or descriptions of the study used to obtain informed consent) will be 
submitted by [CONTACT_321187]/REB/IEC .  Approval from the IRB/REB/IEC must be 
obtained before starting the study and should be d ocumented in a letter to the Investigator 
specifying the following:  
• Protocol number;  
• Protocol version;  
• Protocol date;  
• Documents reviewed; and  
• Date on which the committee met and granted the approval.  
Any amendments to the protocol will require IRB/REB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
The Investigator will be responsible for the following:  
• Providing written summaries of the status of th e study to the IRB/REB/IEC’s 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/REB/IEC;  
• Notifying the IRB/REB/IEC of serious adverse events or other significant safety 
findings as required by p rocedures established by [CONTACT_1201]/REB/IEC.  
10.9.4.  Informed Consent  
The Investigator (or designee) is responsible for obtaining written informed consent from each 
study participant prior to any study activities .  To help the individual make an informed decision 
about participating, the Investigator (or designee) shall discuss with the potential participant the 
purpose of the research, procedures, risks, benefits, alternative options to participating, 
confidentiality, how to contact [CONTACT_3462], and the patient’s  rights .  Potential participants 
must be informed that their participation is voluntary and must be given ample time to ask the 
Investigator questions and obtain clarifications regarding the study prior to providing consent.  
The Investigator must utilize a n IRB/REB/IEC -approved informed consent form for 
documenting written informed consent that contains all elements required by [CONTACT_30104], state, 
local, and institutional regulations or requirements .  Each informed consent form will be 
appropriately signed and  dated by [CONTACT_12718]’s legally authorized representative 
and the person obtaining consent.  
As described in Section  10.6, patients must be re -consented to participate in the study if a 
protocol amendment is made that substantially alters the study design or the potential risks or 
burden to patients.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723089] assure that patients’ anonymity will be strictly  maintained and that their 
identities are protected from unauthorized parties .  Only patient number (i.e., not names) and 
date of birth (as allowed) should be recorded on any form or biological sample submitted to the 
Sponsor, IRB/REB/IEC, or laboratory .  The Investigator must keep a Screening log showing 
codes, names, and addresses for all patients screened and for all patients enrolled in the study.  
The Investigator agrees that all information received from the Sponsor, including, but not limited 
to, the IB, protocol, eCRFs and other study forms, the investigational drug, and any other study 
information, remain the sole and exclusive property of the Sponsor during the conduct of the 
study and thereafter .  This information is not to be disclosed to any thir d party (except employees 
or agents directly involved in the conduct of the study or as required by [CONTACT_2371]) without prior 
written consent from the Sponsor .  The Investigator further agrees to take all reasonable 
precautions to prevent the disclosure by [CONTACT_550411].  
10.9.6.  Study Files and Retention of Records  
The Investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the st udy data to be subsequently verified .  These documents should 
be classified into at least the following two categories:  
1. Investigator’s study file .  The Investigator’s study file will contain the IB, 
protocol/amendments, IRB/REB/IEC and governmental approva l with correspondence, 
informed consent forms, drug records, staff curriculum vitae, authorization and training 
forms, and other appropriate documents and correspondence.  
2. Patient clinical source documents .  The required source data should include the follo wing 
for each patient:  
• Patient identification (name, date of birth, sex);  
• Documentation that the patient meets eligibility criteria, (e.g., history, physical 
examination, and confirmation of diagnosis to support inclusion and exclusion 
criteria);  
• Participa tion in the study (including study number);  
• Study discussed and date of informed consent;  
• Dates of all visits;  
• Documentation that protocol -specific procedures were performed;  
• Results of efficacy parameters, as required by [CONTACT_760];  
• Start and end date ( including dose regimen) of Study Treatment (drug dispensing and 
return should be documented as well);  
• Record of all adverse events and other safety parameters (start and end date, and 
causality and intensity as assigned by [CONTACT_737]);  
• Concomitant me dication (including start and end date); and  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 71 • Date of study completion and reason for early discontinuation, if applicable.  
All clinical study documentation must be retained by [CONTACT_31201] [ADDRESS_723090] approval of a marketing a pplication in an ICH region (i.e., [LOCATION_002], Europe, or 
Japan) and until there are no pending or contemplated marketing applications in an ICH region; 
or, if no application is filed or if the application is not approved for such indication, until [ADDRESS_723091] and study -related materials, 
documentation of financial aspects of the study, insurance statement, and signed agreement 
between the involved parties, dated and documented IR B/REB/IEC approval, approval of 
regulatory authorities as applicable, decoding procedures for blinded studies, curriculum vitae 
and all training records of study site personnel, and all correspondence pertaining to the conduct 
of the study.  
Should the Inve stigator wish to assign the study records to another party or move them to another 
location, the Sponsor must be notified in advance.  
If the Investigator cannot guarantee this archiving requirement at the study site for any or all of 
the documents, special  arrangements must be made between the Investigator and the Sponsor to 
store these in sealed containers outside of the site so that they can be returned sealed to the 
Investigator in case of a regulatory audit .  When source documents are required for the c ontinued 
care of the patient, appropriate copi[INVESTIGATOR_69786].  
10.9.7.  Electronic Case Report Forms  
For each patient enrolled, an eCRF must be completed and signed by [CONTACT_97728]-Investigator (as appropriate) listed on  Food and Drug Administration Form 1572 and/or 
other appropriate local health authority documents within a reasonable time period after data 
collection .  This also applies to records for those patients who fail to complete the study (even 
during a pre -randomization Screening Period if an eCRF was initiated) .  If a patient withdraws 
from the study, the reason must be noted on the eCRF .  If a patient is withdrawn from the study 
because of a treatment -limiting adverse event, thorough efforts should be made to clearly 
document the outcome.  
10.9.8.  Investigational Product Accountability  
The Investigator or Investigator’s designee (e.g., pharmacist) is responsible for ensuring 
adequate accountability (including dates and lot numbers) of all used and unused Study 
Treatment  (active and placebos) .  This includes acknowledgment of receipt of each shipment of 
study product (quantity and condition), patient dispensing records, and returned or destroyed 
study product .  Dispensing records will document quantities received from the  Sponsor and 
quantities dispensed to patients, including lot number, date dispensed, Patient Number, and the 
initials of the person dispensing the Study Treatment.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 72 At study initiation, the study monitor will evaluate the site’s standard operating procedure  for 
investigational medicinal product disposal/destruction in order to ensure that it complies with the 
Sponsor requirements .  Drug may be returned (by [CONTACT_2037]) or destroyed on -site, if 
appropriate per site standard operating procedures (SOPs) .  At th e end of the study, following 
final drug inventory reconciliation by [CONTACT_2037], the study site will dispose of and/or destroy 
all unused Study Treatment supplies, including empty containers, according to these procedures .  
If the site cannot meet the Spo nsor’s requirements for disposal, arrangements will be made 
between the site and the Sponsor (or designee) for destruction or return of unused investigational 
medicinal product supplies.  
All drug supplies and associated documentation will be periodically reviewed and verified by [CONTACT_69878].  
10.10.  Sponsor -Specific Responsibilities  
10.10.1.  Study Report  
A clinical study report will be prepared and provided to the regulatory authorities .  The Sponsor 
will ensure that the report meets the standards set out in the ICH Guideline for Structure and 
Content of Clinical Study Reports (ICH E3) .  Note that an abbreviated report may be prepared in 
certain cases.  
10.10.2.  Posting of Informat ion on Public ly Available Clinical Trial Registers  
Study information from this protocol will be posted on publicly available clinical trial registers 
before enrollment of patients begins .  Results will be posted as required.  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723092] function :  Report from the standardisation sub -committee of the international 
continence society .  Neurourol Urodyn 2002;21:167 –78. 
2. Biers SM, Reynard JM and Brading AF .  The effects of a new selective β3 - adrenoceptor 
agonist (GW427353) on spontaneou s activity and detrusor relaxation in human bladder .  
BJU International 2006;98 :  1310 -4. 
3. Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, Khemiri A, Siddiqui 
E, Wagg A .  Persistence and Adherence with Mirabegron versus Antimuscarinic Agen ts 
in Patients with Overactive Bladder :  A Retrospective Observational Study in [LOCATION_006] 
Clinical Practice .  Eur Urol .  2017 Sep;72(3):389 -399. 
4. Chapple CR, Kaplan S, Mitcheson HD, Klecka J, Cummings J, Drogendijk T, Dorrepaal 
C, Martin NE .  Randomized, double -blind, active -controlled Phase III study to assess the 
ling-tern safety and effiocacy of mirabegron in overactive bladder (OAB) .  Presented at 
European Association of Urology Annual Meeting, February 2012.  
5. Chapple CR, Wyndaele JJ, van Kerrebroeck P, Radzisze wski P, Dvorak V, Boerrigter P .  
Dose -ranging study of once -daily mirabegron (YM178), a novel selective β [ADDRESS_723093], in patients with overactive bladder (OAB) .  Poster presentation at 
the 2010 European Urologic Association Annual Meeting, Barc elona, Spain.  
6. Chapple CR, Yamaguchi O, Ridder ALJ, Carl S, Mattiasson A, Aramburu MAL, et al .  
Clinical proof of concept study (BLOSSOM) shows novel β3 adrenoceptor agonist 
YM178 is effective and well tolerated in the treatment of symptoms of overactive 
bladder .  Poster presentation at the 2009 European Urologic Association Annual Meeting, 
Milan, Italy.  
7. D’Souza AO, Smith MJ, Miller L -A, Doyle J, Ariely R .  Persistence, adherence, and 
switch rates among extended -release and immediate -release overactive bladd er 
medications in a regional managed care plan .  J Manag Care Pharm 2008;14(3) :  
291-301. 
8. FDA Guidance for Industry .  Drug -Induced Liver Injury :  Premarketing Clinical 
Evaluation .  July 2009 .  Available at :  
http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf .  Accessed :  
[ADDRESS_723094] R, Walker R, Yu O, Crane P, 
Larson,  EB.  Cumulative use of strong anticholinergic medications and incident 
dementia .  JAMA Intern Med 2015;175(3) :  401-407. 
10. Gray SL, Hanlon JT .  Anticholinergic medication use and dementia :  latest evidence and 
clinical implications .  Ther Adv Drug Saf 2016; 7(5):  217-224. 
11. Kaidoh K, Igawa Y, [COMPANY_005] H, Yamazaki Y, Akahane S, Miyata H, Ajisawa Y, 
Nishizawa O, Andersson KE .  Effects of selective [beta]2 and [beta]3 - Adrenoceptor 
agonists on detrusor hyperreflexia in conscious cerebral infarcted rats .  J Urol 200 2;168 :  
1247 -52. 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723095], Benson SR, Anderson MJ .  Immediate -release oxybutynin 
versus tolterodine in detrusor overactivity :  a population analysis .  Pharmacotherapy .  
2000;20(4) :  470-475. 
13. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ .  How widespread are 
the symptoms of an overactive bladder and how are they managed ?  A population -based 
prevalence study .  BJU International 2001;87 :  760-6. 
14. Rabin R, Gudex C, Selai C, Herdman M .  From translation to version management :  a 
history and review of methods for the cultural adaptation of the EuroQol five -
dimensional questionnaire .  Value Health 2014 Jan;17(1):70 -76, 01 -01-2014.  
15. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al .  
Prevalence and burden of  overactive bladder in the [LOCATION_002] .  World J Urol 2003;20 :  
327-36. 
16. [COMPANY_005] H, Yamazaki Y, Akahane M, Igawa Y, Ajisawa Y, Nishizawa O .  Role of the β3 -
adrenoceptor in urine storage in the rat :  comparison between the selective β3 -
adrenoceptor agonist,  CL316, 243, and various smooth muscle relaxants .  J Pharm Exp 
Ther 2000;293 :  939-45. 
17. [COMPANY_005] H, Yamazaki Y, Igawa Y, Kaidoh K, Akahane S, Miyata H, Nishizawa O, 
Akahane M, Andersson KE .  Effects of β3 -adrenoceptor stimulation on prostaglandin E2 -
induced b ladder hyperactivity and on the cardiovascular system in conscious rats .  
Neurology and Urodynamics 2002;21 :  558-65. 
18. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, and Wein A .  tolterodine oncedaily :  
superior efficacy and tolerability in the treatment of the overactive bladder .  
Urol 2001;57 :  414–21. 
19. Woods M, Carson N, Norton N, Wesley S, Jeffery H, Argentieri TM .  Efficacy of the 
[Beta][ADDRESS_723096] CL -316243 on experimental bladder hyperreflexia 
and detrusor instability in the rat .  J Urol 2001;166 :  1142 -7. 
20. Yamaguchi O .  β3-adrenoceptors in human detrusor muscle .  Urology 2002;59 
(Supplement 5A) :  25-29. 
 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 75 APPENDICES  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723097] computerized tomography  
DBP  diastolic blood pressure  
DDI drug-drug interaction  
ECG  electrocardiogram  
eCRF  electronic case report form  
eDiary  electronic diary  
eGFR  estimated glomerular filtration rate  
EQ-5D European Quality of Life -5 dimension  
ER extended release  
EU European Union  
FAS-Ext full analysis set  extension  
FAS-Ext-I full analysis set  extension  for incontinence  
FDA  ([LOCATION_002]) Food and Drug Administration  
GCP  good clinical practice  
GI gastrointestinal  
HRQL  health -related quality of life  
IB Investigator's Brochure  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723098] level  
NVU  nighttime voids associated with urgency  
OAB  overactive bladder  
OAB -q Overactive Bladder Questionnaire  
OAB -q LF  Overactive Bladder Questionnaire Long Form  
PD pharmacodynamic(s)  
PDE 5  phosphodiesterase type 5  
PGI Patient Global Impression  
P-gp P-glycoprotein  
PP-Ext per-protocol extension population  
PP-Ext-I per-protocol extension population for incontinence  
PRO  patient -reported outcome(s)  
PVR  patient void residual  
QD once daily  
QTc corrected QT  
RBC  red blood cell  
REB  research ethics board  
REML  restricted (or residual) maximum likelihood  
SAE  serious adverse event  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723099] infection  
UUI urge urinary incontinence  
WBC  white blood cell  
WHO -DDE  World Health Organization Drug Dictionary Enhanced  
WPAI -US Work Productivity and Activity Impairment Questionnaire -Urinary 
Symptoms  
β3-AR beta-3 adrenergic receptor  
β-AR beta adrenergic receptor  
β-hCG  beta-human chorionic gonadotropin  
 
 
  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 79 APPENDIX  2. ALGORITHM FOR ASSESS ING LABORATORY VALUE S 
For all laboratory values obtained at pre -study evaluation:  
1. If all values are normal, the patient may enter the study.  
2. If a value is outside the normal range, the following choices are  available:  
• The patient may be excluded from the study;  
• The abnormal test may be  repeated.  
• The result may be deemed “Not Clinically Significant” and the patient may be 
enrolled in the study.  
3. If the Investigator decides to repeat an abnormal test and if it is within the normal range, 
the patient may enter the study.  
4. If the Investigator  decides to repeat an abnormal test and if the repeat test is still 
abnormal, the Investigator will evaluate the potential patient with a complete history and 
physical examination, looking especially for diseases that could result in an abnormality 
in the laboratory value in question .  If such diseases can be excluded, and if the 
Investigator feels that the abnormal laboratory value is not clinically relevant, then the 
patient may enter the study .  The Urovant clinical monitor will be included in the 
decisi on of whether or not to enroll the patient in the study.  
5. If there is any clinical uncertainty regarding the significance of an abnormal value, the 
patient will be excluded from the study.  
  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 80 APPENDIX  3. APPROXIMATE BLOOD/TI SSUE VOLUMES 
DRAWN/COLLECTED BY S AMPLE TYPE  
 Number of 
collections  Approximate 
amount per 
collection  Total Amount  
Hematology  4 10 mL 40 mL 
Serum/Plasma Chemistry  4 10 mL 40 mL 
Total  80 mL 
  
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | [ADDRESS_723100] 
abnormalities resolve to baseline.  
Monitor liver tests per the applicable schedule in Appendix -4 Table 1, and per the investigations 
in Appendix -4 Table 2.  If close monitoring is not possible, Study Treatment should be withheld, 
even if the results do not meet the criteria for withholding in Section  8.6.1 . 
The medical monitor should be contact[CONTACT_187662] -up tests and 
frequency of follow -up tests for a patient.  
Appendix -4 Table 1 Monitoring of Liver Tests for Potential Drug -Induced Liver Injury  
Results  Frequency for Repeating Liver (AST, ALT, 
Bilirubin [Total and Direct]), Alkaline 
Phosphatase, and INR Testsa  
If AST or ALT ≥ [ADDRESS_723101] and total bilirubin 
> [ADDRESS_723102] or INR > 1.[ADDRESS_723103] ≥ [ADDRESS_723104] abnormalities improve AND the 
patient is asymptomatic  Frequency may decrease  
Abbreviations :  ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international 
normalized ratio; ULN, upper limit of normal  
a. Review frequency of monitoring with medical monitor for an individual patient, in case o f questions  
 
Clinical Study Protocol  RVT -901-3004  
Urovant Sciences GmbH  Effective:  12-APR -2019  
Confidential  Page | 82 Appendix -4 Table 2 Investigations of Alternative Causes for Abnormal Liver Tests  
Obtain a detailed history and perform a physical examination:  
• Detailed history of symptoms (e.g., right upper quadrant pain, fati gue, nausea, 
vomiting, and fever);  
• Prior and concurrent disease or illnesses;  
• Exposure to environmental (e.g., travel, new sexual exposure, exposure to ill family 
members or coworkers, etc.) and/o r industrial chemical agents;  
• Prior and concurrent use of alcohol, recreational drugs, and special diets;  
• Concomitant use of medications (including nonprescription medicines and herbal 
and dietary supplements), plants and mushrooms;  
• Physical examination.  
Recommended tests:  
Also perform additional tests as clinic ally indicated or in consultation with a gastroenterologist 
or hepatologist.  
• Repeat liver tests as per Appendix -4 Table 1a; 
• Obtain gamma -glutamyl transferase, albumin, INR, and glucose in conjunction 
with repeat liver tests;  
• Complete blood count with differential to assess for eosinophilia;  
• Serum acetaminophen (paracetamol) concentration;  
• Obtain viral serologies for hepatitis A, B, C, D, and E;  consider testing for Epstein 
Barr virus;  
• Evaluate for alcoholic hepatitis, nonalcoholic steatohepatitis, biliary tract disease, 
autoimmune hepatitis, etc.;  
• Serology for celiac disease;  
• Appropriate liver imaging; and  
• Hepatology consult (liver biopsy may be cons idered in consultation with a 
hepatologist or gastroenterologist).  
Abbreviations :  INR, international normalized ratio  
a. If the first follow -up testing does not confirm the initial abnormal liver test results, review any 
additional follow -up monitoring with  the medical monitor.  
 
 